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ABSTRACT: 34 
 35 
A series of cationic allyl palladium complexes [Pd(h3-CH3-C3H5)(P-P)]X (X ¼ PF6, 2a-c, 2e; and X ¼ 36 
BPh4, 3a, 3b, 3d, 3e) and [Pd(h3-1,3-Ph2-C3H3)(P-P)]X (X ¼ PF6, 6b; and X ¼ BPh4, 7a) have been 37 
prepared. The bis(diamidophosphite) ligands (P-P) contain a diazaphospholidine terminal fragment 38 
derived from (R,R)- and (S,S)-N,N’-dibenzyl- and (R,R)-N,N’-dimethyl-cyclohexane-1,2-diamines and 39 
dialcoxy bridging fragment derived from (R,R)- and (S,S)-butanediol, (R,R)-cyclohexanediol, (4R,5R)- 40 
and (4S,5S)-4,5- di(hydroxymethyl)-2,2-dimethyl-1,3-dioxolane and (R)- and (S)-binaphthol. 41 
Complexes [Pd(h3-CH3- C3H5l)P2]X (X ¼ PF6, 4f, 4g; and X ¼ BPh4, 5f), where P are monodentate 42 
diamidophosphite ligands with diazaphospholidine heterocyclic backbone obtained from (R,R)- and 43 
(S,S)-N,N’-dibenzylcyclohexane-1,2- diamine and alcoxy groups coming from (R)-phenyl-ethanol and 44 
(S)-borneol have been also prepared. Neutral palladium complexes [PdCl2(P-P)] (1a, 1c) were 45 
synthesized to prove the C2 symmetry of the P-P ligand. The new compounds were fully characterized 46 
in solution by NMR spectroscopy. The X-ray crystal structure determination for 2e-(R,R,Ral,Ral;R,R) 47 
and 1a-(S,S;Sal,Sal;S,S) has been achieved. 48 
The new allyl-palladium complexes were applied in the asymmetric allylic substitution reaction of the  49 
benchmark substrate rac-3-acetoxy-1,3-diphenyl-1-propene with dimethyl malonate and benzylamine as 50 
nucleophiles in order to test their catalytic potential. The best results were obtained with the 3a-51 
(R,R;Ral,- Ral;R,R) precursor (up to 84% ee) while complexes with the e ligand derived from the (R,R)-52 
N,N’-dimethylcyclohexane- 1,2-diamine terminal fragment resulted inactive in the process. The 53 
influence of the nature and the absolute configuration of both the bridging and the terminal fragments of 54 
the bis(diamidophosphite) ligand on the asymmetric induction is discussed. A preliminary study of the 55 
anion effect (PF6    vs. BPh4 - ) on the activity and the enantioselectivity of the Pd-catalysed allylic 56 
substitution has also been performed. 57 
 58 
 59 
  60 
1. INTRODUCTION 61 
 62 
The palladium-catalyzed asymmetric allylic substitution is a useful synthetic method for 63 
enantioselective formation of carboncarbon and carbon-heteroatom bonds [1]. The wide variety of chiral 64 
ligands for highly enantioselective allylic substitutions includes bidentate P- or N-based ligands, mixed 65 
bidentate P-N, P-S and P-P0 ligands and monodentate phosphorus donors [2]. Among P-donor ligands 66 
those with P-heteroatom bonds, such as phosphites (3P-O), phosphoramidites (2P-O, 1P-N) and 67 
diamidophosphites (2P-N, 1P-O) are good alternatives to chiral phosphines (3P-C), because they can be 68 
obtained straightforwardly through a modular approach by reacting chiral alcohols or amines with 69 
phosphorus halides, providing families of ligands with a large structural and stereochemical diversity. 70 
They also provide ample opportunity for fine-tuning their donor-acceptor and steric properties by 71 
incorporation of an heteroatom directly bound to the phosphorus atom and variation of the O- and N-72 
containing chiral building blocks as well as the substituents on the N atom [3]. Bidentate phosphites [4] 73 
and mono- [5] and bisphosphoramidites [6] have been successfully applied in allylic alkylation reaction. 74 
The use of diamidophosphites is mostly focused on the P-stereogenic bis(diamidophosphite) ligands 75 
with 1,3,2-diazaphospholidine rings and several diols such as 1,4:3,6 dianhydro-D-manitol [7], N-76 
benzyltartarimide [8], N-naphthyltartarimide [9], binaphthol [10], resorcinol and hydroquinone [11] as 77 
frameworks. Monodentate Pstereogenic diamidophosphites have also been found to be efficient ligands 78 
for palladium catalyzed asymmetric allylic substitution [12]. All of them contain a cyclic structure in 79 
which the phosphorus atom is part of the heterocyclic ring, this feature is responsible for an increase in 80 
ligand stability.  81 
We have been interested in the synthesis of enantiopure monodentate and bidentate diamodophosphite 82 
ligands with heterocyclic fragments derived from N,N’-substituted cyclohexyldiamine and N,N’-83 
dimethyl-1,1’-binaphthyldiamine and several chiral alcoxy groups.We have recently described the 84 
application of two different families of monodentate diamidophosphite ligands in the asymmetric Pd-85 
catalyzed hydrovinylation reaction [13] and in the allylic substitution in ionic liquids [14]. The bidentate 86 
C2 diamidophosphite ligandswere applied in the Rh-catalyzed asymmetric hydrogenation of benchmark 87 
olefins attaining excellent enantioselectivities with most of them [15]. Cationc palladium complexes 88 
with bis(diamidophosphite) ligands containing N,N’-dimethyl-1,1’-binaphthyldiamine as heterocyclic 89 
terminal fragment have been tested as catalyitic precursors in the allylic substitution process affording 90 
enantiomeric excesses of up to 85% [16]. These results prompted us to explore the performance of the 91 
similar N,N’-substituted cyclohexyldiamine diamidophosphite ligands in the same reaction. 92 
In this paper we describe the synthesis and characterization of new cationic methallyl palladium 93 
complexes [Pd(h3-2-CH3- C3H5)(P-P)][X], and [Pd(h3-2-CH3-C3H5)P2][X] with X ¼ PF6    or BPh4 94 
  , with the new cyclohexyldiamine based ligands a-(S,S;Sal,Sal; S), b-(R,R;Sal,Sal;R,R), c-95 
(R,R;Ral;R,R) and e-(R,R;Ral,Ral;R,R). and the previously described ligands [15] as shown in Fig. 1. 96 
Not many examples of the coordination chemistry of this kind of ligands have been reported in the 97 
literature so far [7a,13,16,17]. The new cationic palladium complexes have been used as catalytic 98 
precursors in the Pd-asymmetric allylic alkylation and amination of the model substrate, rac-3-acetoxy-99 
1,3-diphenyl-1-propene, with the anion derived from dimethyl malonate and benzylamine as 100 
nucleophiles. 101 
This group of complexes was suitable for the comparison of the influence of the nature and absolute 102 
configuration of both the terminal and bridging fragments of the bis(diamidophosphite) ligands on the 103 
asymmetric induction. In addition the effect of the different BPh4    and PF6    anions on the activity 104 
and enantioselectivity of the reaction has been evaluated. Moreover the importance of the monodentate 105 
or bidentate nature of the ligands and their influence on the activity and selectivity of the process can be 106 
discussed. 107 
 108 
 109 
 110 
 111 
  112 
2. RESULTS AND DISCUSSION 113 
 114 
2.1. Synthesis and characterization of diamidophosphite ligands 115 
The new chiral C2-symmetric bis(diamidophosphite) ligands a, b, c, d and e depicted in Fig. 1 were 116 
synthesised via two consecutive condensation reactions from enantiomerically pure diamines and the 117 
corresponding diols in the presence of a base following our previously reported methods [15,16]. The 118 
chiral monodentate diamidophosphite ligands f and g (Fig. 1) were prepared as previously described by 119 
us [13]. As extensive manipulation led to ligand decomposition, they were used without purification in 120 
the formation of the corresponding palladium complexes. The preparation and characterization of the 121 
new a-(S,S;Sal,Sal;S,S), b-(R,R;Sal,Sal;R,R), c-(R,R;Ral;R,R) and e-(R,R;Ral,Ral;R,R) ligands is 122 
reported in the experimental section of this paper. 123 
 124 
2.2. Synthesis and characterization of neutral complexes [PdCl2(PP)] 125 
The reaction between [PdCl2(COD)] and two selected bis(diamidophosphite) ligands was studied in 126 
order to evaluate the coordination and the structural features of the ligands in an ideal environment of 127 
C2 symmetry. The reaction of equimolar amounts of the corresponding bis(diamidophosphite) (a-128 
(S,S;Sal,Sal;S,S) or c- (R,R;Sal;R,R)) and [PdCl2(COD)] in toluene/dichloromethane solution at room 129 
temperature gave nearly quantitative yields of [PdCl2(P-P)], 1a-(S,S;Sal,Sal;S,S) and 1c-(R,R;Sal;R,R) 130 
(Scheme 1). 131 
The 31P NMR spectra of the palladium complexes showed one phosphorus resonance at 111.4 ppm for 132 
1a and at 101.7 ppm for 1c, shifted upfield with respect to the corresponding free bis(diamidophosphite) 133 
ligand and suggesting that the C2 symmetry of the free ligand is maintained upon coordination to the 134 
PdCl2 fragment. 13C NMR spectra for 1a and 1c showed the expected two signals for the four chiral 135 
carbon atoms of the cyclohexyldiamine ring. However, the signals of the four benzylic carbon atoms 136 
appeared as two pseudotriplets arising from the overlap of two doublets with very similar chemical shift 137 
and coupling constant (JCP ~7 Hz) indicating certain loss of the expected symmetry. It should be noted 138 
that the corresponding free ligands showed two doublets with very different coupling constants (about 139 
40 and 20 Hz) [15]. 1H NMR for 1a and 1c showed more than four sets of signals belonging to the eight 140 
benzylic protons probably because of a different disposition of the aromatic rings of the benzylic groups 141 
in solution and in accordance with a partial loss of the symmetry of the ligand. 142 
 143 
2.3. Synthesis and characterization of cationic allylpalladium complexes [Pd(h3-2-CH3-C3H4)(P-P)]X 144 
and [Pd(h3-2-CH3-C3H4)]P2]X 145 
Reaction of the organometallic precursor [Pd(h3-2-CH3-C3H4)(m-Cl)]2 with the appropriate amount of 146 
ligand (2 equivalents for a-e, 4 equivalents for f-g) in the presence of an excess of sodium 147 
hexafluorophosphate afforded ionic allylpalladium complexes of general formula [Pd(h3-2-CH3-148 
C3H4)(P-P)]PF6 (2a-c and 2e) and [Pd(h3-2-CH3-C3H4)]P2]PF6 (4f and 4g) (Scheme 2). Some 149 
compounds with the BPh4 counterion, [Pd(h3-2-CH3-C3H4)(P-P)]BPh4 (3a, 3b, 3d and 3e) and [Pd(h3-150 
2-CH3-C3H4)P2]BPh4 (5f) were also prepared by addition of a little excess of NaBPh4 in MeOH to a 151 
dichloromethane solution of the hexafluorophosphate compound. 152 
The new compounds were obtained as white yellow solids in low to moderate yields, stable under inert 153 
atmosphere at room temperature and fully characterized in solid state and in solution by the usual 154 
techniques. Relevant NMR data are summarized in Table 1. 31P NMR spectroscopy confirms the 155 
existence of only one isomer in both kind of cationic complexes. Two sharp doublets showing a roof 156 
effect are observed in all compounds, indicating the loss of C2 symmetry of the Pd(P-P) or the PdP2 157 
fragment in the presence of the allyl ligand as described for related cationic palladium methallyl 158 
bis(diamidosphosphite) [16] or monodentate diamidophosphite complexes [14,17]. Upon coordination to 159 
the palladium atom, the phosphorus atoms in both bidentate and monodentate diamidophosphite 160 
experience an upfield shift (5e17 ppm) with respect to the free ligand, probably due to their relative low 161 
s-donor character based on the high JPSe value previously reported [13,15]. Complexes containing 162 
different diastereoisomers of the same ligand, 2a-(S,S;Sal,Sal;S,S) and 2a- (R,R;Sal,Sal;R,R), 2b-163 
(R,R;Ral,Ral;R,R) and 2b-R,R;Sal,Sal;R,R), 2c- (R,R;Ral;R,R) and 2c-R,R;Sal;R,R), showed slightly 164 
different 31P chemical shift and 2JPP coupling constants. 165 
Bidimensional HSQC 1H-13C experiments were necessary to unequivocally assign 1H and 13C NMR 166 
spectra. 1H NMR spectra revealed the existence of a single palladium-allyl isomer for each complex, 167 
showing four signals for the terminal hydrogen atoms of the allyl moiety in accordance with the lack of 168 
symmetry of the complexes. The two signals of the anti protons usually appeared as doublets due to the 169 
coupling with the phosphorus atom in trans position (2a, 2b, 2e, 3a, 3b, 3d, 3e, 4f and 5f) while the two 170 
syn protons were observed as two broad singlets, but as doublets in 2b with smaller values of JHP 171 
compared to the anti ones. Obviously, the lack of symmetry can also be seen for the signals of the 172 
diamidophosphite ligands in complexes 2 and 3, giving some duplicated proton signals relative to the 173 
free ligands. All diastereotopic benzylic protons of the benzylcyclohexil fragment are different and 174 
accordingly up to six sets of signals are seen in the case of both diastereoisomers of 2c and five for 3d-175 
(R,R;Ral,Ral;R,R). Some of these signals are well defined showing a triplet or a doublet of doublets 176 
pattern indicating that the diastereotopic benzylic protons have different coupling constants 3JPH. In 177 
complexes with the  methylcyclohexil terminal fragment (2e and 3e), N-methyl protons appear as four 178 
doublets but in this case with very similar coupling constant values (3JHP around 15.0 Hz). Proton 179 
signals of the monodentate diamidophosphite ligands f and g are also duplicated in the spectrum of the 180 
allyl-palladium complexes 4f, 5f and 4g. It is worth noting that all the signals of cationic complexes 181 
containing BPh4    anion (3a, 3b, 3e and 5f) are shifted upfield compared to the corresponding 182 
complexes with PF6    anion (2a, 2b, 2e and 4f). This may be attributed to the local anisotropic effects 183 
associated with the presence of the phenyl groups in the BPh4    close enough to the complex cation in 184 
CDCl3 to shift the signals upfield. Similar results have been already reported in the literature for allyl-185 
palladium complexes with nitrogen donor ligands suggesting ion-pairing in CDCl3 solution [19]. 186 
13C NMR spectra of palladium complexes with bidentate and monodentate diamidophosphite ligands 187 
show the terminal allylic carbon atoms as two well resolved doublet of doublets or broad doublets and 188 
the central carbon atom as a pseudotriplet because of the coupling with both phosphorus atoms. The 189 
larger differences between the chemical shifts of the terminal allylic carbon atoms appear in 2c-190 
(R,R;Sal;R,R) (2.6 ppm) and in 4g-(R,R;Sal) (4.5 ppm). As reported in the experimental part, 13C NMR 191 
spectra show four doublets with two different coupling constant values corresponding to the benzylic 192 
carbon substituent of the cyclohexilamine fragment (2a-c, 3a, 3b, 3d, 4f, 5f and 4g) as well as for the 193 
methyl substituent in complexes with e ligand suggesting different orientations of these amino 194 
substituents with respect to the P-Pd bond as it has been previously reported [12,16,19]. 195 
Bidimensional NOESY experiments were performed for all the complexes (see supporting material). 196 
Only for complexes 2c- (R,R;Sal;R,R), 2e-(R,R;Ral,Ral;R,R) and 3e-(R,R;Ral,Ral;R,R) NOE contacts 197 
between the allyl fragment and the bis(diamidophosphite) ligand can be observed (see Fig. 2). Moreover 198 
in the NOESY experiment of 2e-(R,R;Ral,Ral;R,R) exchange signals between Hsyn- Hsyn, Hanti-Hanti, 199 
and Hsyn-Hanti protons were detected indicating that the dynamic behaviour takes place through the 200 
two well-known pseudorotation and h3-h1-h3 mechanisms [13,16]. On the other hand exchange signals 201 
between NMe groups have been also detected. 202 
 203 
2.4. X-ray structures of 1a-(S,S;Sal,Sal;S,S) and 2e-(R,R;Ral,Ral;R,R) 204 
Single crystals of 1a-(S,S;Sal,Sal;S,S) and 2e-(R,R;Ral,Ral;R,R) suitable for X-ray analysis were 205 
obtained by slow diffusion of hexane into a saturated dichloromethane solution of the complexes at 206 
 room temperature or at 4 C respectively. The molecular structure and a selection of bond lengths and 207 
angles are shown in Fig. 3 (1a- (S,S;Sal,Sal;S,S)) and Fig. 4 (2e-(R,R;Ral,Ral;R,R)). Both complexes 208 
have a slight distorted square planar geometry around the palladium atom. Bond distances and angles in 209 
the coordination sphere are in the range described for related cationic allyl palladium complexes [14,16]. 210 
The structure for 1a-(S,S;Sal,Sal;S,S) consists of discrete units of the neutral compound separated by 211 
typical van derWaals distances and is depicted in Fig. 3. The sligthly distorted square planar 212 
coordination of [PdP2Cl2] in 1a, showed the P-Pd-P bite angle close to    90  (90.76(4) ) and for the Cl-213 
Pd-  Cl angle a value of 92.43(4) . The bridge of the bis(diamidophosphite) ligand is symmetrically 214 
located in relation to the coordination plane but the arrangement of the benzyl groups is not identical in 215 
each moiety of the ligand (Fig. 3b). The aromatic rings of the benzyl substituents of N3 and N4 are 216 
situated above and below the plane defined by atoms N4P2N3, with a trans disposition, while those of 217 
N1 and N2 are placed on the same side of the plane defined by atoms N1P1N2, with a cis disposition. 218 
This fact is also reflected, as depicted above, in the 1H NMR spectrum of the neutral complex in 219 
solution, in which more than four signals for the benzylic protons appear. 220 
The structure for 2e-(R,R;Ral,Ral;R,R) consists of two similar non-equivalent discrete units of the 221 
cationic complex and hexafluorophosphate anions separated by typical van der Waals distances. One of 222 
the organometallic cations is depicted in Fig. 4. The two terminal carbon atoms of the allyl group are 223 
approximately equidistant from the palladium centre. Moreover, the carboncarbon bond lengths of the 224 
h3-allyl group are nearly equal, which is in accordance with the similar chemical shifts observed in the 225 
13C NMR spectra. No significant rotated orientation of the allyl group around the Pd-allyl axis is 226 
observed. The bite angle P-Pd-P is  102.51(9)  while the Ct-Pd-  Ct angle is 67.4(4) . This bite angle is 227 
smaller than that observed for the allylic complex containing a similar bidentate diamidophosphite 228 
ligand with the same bridge but with the bisdimethylbinaphthyldiamine terminal fragment  (105.60(3) ) 229 
[16] and markedly different than that observed for complex 1a. This fact indicates that the presence of 230 
the two chlorine atoms leads to a narrower bite angle. 231 
For both compounds the Pd-P distance is dependent on the bite angle of the ligand. As described by van 232 
Leeuwen and coworkers [20] for allylpalladium complexes with bidentate diphosphines a smaller bite 233 
angle results in a smaller Pd-P distance. It is 2.2172(11) Å for 1a and 2.276(2) Å for 2e. From the 234 
limited number of structures containing the PNNO skeleton, it should be noted that the P-N bond 235 
distances of the bis(diamidophosphite) coordinated ligand in complexes 2e and 1a are in the range of 236 
those described for both either mono and bidentate diamidophosphites in neutral and cationic allylic 237 
palladium complexes [13,14,16] and in boranediamidophosphite compounds [21]. The P-N bond 238 
distances for both compounds range between 1.641 Å and 1.678 Å and suggest partial multiple-bond 239 
character when compared to the normally accepted bond lengths (P-N bond, 1.77 Å and P]N bond 1.57 240 
Å) [22]. Moreover the P-N bond lengths of the coordinated bis(diamidophosphite) ligands are smaller 241 
than those observed for similar free ligands [23]. 242 
 243 
2.5. Asymmetric allylic substitution reactions 244 
To evaluate the potential of diamidophosphite ligands a-g in the asymmetric allylic substitution, the 245 
cationic palladium complexes [Pd(h3-2-CH3-C3H4)(P-P)]X, 2a-c, 3a, 3b, 3d, 3e, and [Pd(h3-2-CH3-246 
C3H4)P2]X, 4f, 4g and 5f, were tested as catalytic precursors using the model substrate rac-3-acetoxy-247 
1,3-diphenyl-1-propene (rac-I), with sodium dimethyl malonate and benzylamine as nucleophiles 248 
(Scheme 3). The reactions were performed in CH2Cl2 at room temperature for 24 h. Under these 249 
conditions, the allylic acetate rac-I was converted to the desired products II or III in variable yields. The 250 
results are summarized in Table 2. 251 
When palladium complexes [Pd(h3-2-CH3-C3H4)(P-P)]X and [Pd(h3-2-CH3-C3H4)(P)2]X are used as 252 
precursors in the allylic alkylation reaction the conversion of the allylic acetate rac-I to the desired 253 
product II takes place in moderate to good yields (50e100% at 24 h reaction time). In general terms, the 254 
activity is lower than that reported for complexes with similar diamidophosphite ligands but with a 255 
terminal fragment derived from binaphtyldiamine [16]. Complexes 1e and 2e containing the methyl 256 
substituent in the cyclohexyldiamine fragment of the ligand were not active. This fact contrasts with the 257 
results of Wills et al., who reported that with similar monodentate diamidophosphine ligands the best 258 
activity and enantioselectivity was obtained with the N-methylated ligands [24]. 259 
A wide range of enantioselectivities (20e86% ee) was obtained with all the precursors tested in this 260 
work. The highest ee values appeared with complexes containing both diastereoisomers of a and the d 261 
ligands, which contain the shorter butanediol and ciclohexanediol bridging fragments (entries 1-4 and 262 
11). In contrast, when the precursors contain the diamiophosphite ligand with the binaphthyldiamine 263 
terminal fragment the enantioselectivity increases when the bridging fragment is the long and rigid 264 
binaphtol, and decreases with the short and flexible bridging fragment derived from butanediol [16]. 265 
The absolute configuration of the reaction product II is determined by the absolute configuration of the 266 
carbons of the benzylcyclohexanediamine terminal group. In contrast, ligands with more rigid binaphtol 267 
bridge, this element determines the absolute configuration of the reaction product (entries 8 and 9). 268 
A significant match-mismatch effect was observed between the configuration of the 269 
benzylcyclohexyldiamine and the diol derived bridge within each pair of the diastereoisomers of the 270 
ligands (entries 1 vs 2, 5 vs 6 and 8 vs 9) with 2a-(R,R;Sal,Sal;R,R), 2b- (R,R;Sal,Sal;R,R) and 2c-271 
(R,R;Sal;R,R) being the matched combination with the hexafluorophosphate counterion. Matched and 272 
mismatched combinations of chirality elements were also found for similar ligands containing the 273 
binaphtyldiamine terminal fragment [16] and for P-stereogenic bis(diamidophosphite)-related ligands 274 
[10]. 275 
The allylic alkylation reaction catalyzed with palladium complexes stabilized by monodentate ligands 276 
[25] has been less studied. The results obtained with allyl palladium precursors [Pd(h3-2- CH3-277 
C3H4)P2]X, 4f, 4g and 5f are also summarized in Table 2. Under the same catalytic conditions, up to 278 
100% conversions were reached but with very low enantioselectivies. Here, the configuration of the 279 
major enantiomer was determined by the configuration of the cyclohexyldiamine fragment (entries 11 280 
vs. 12). Therefore a beneficial effect for the asymmetric allylic alkylation reaction in terms of activity is 281 
observed for monodentate versus bidentate diamidophosphite ligands but does not happen the same for 282 
the enantioselectivity. These results contrast with those observed with cationic palladium complexes 283 
containing two similar monodentate diamidophosphites but with binaphthydiamine terminal fragments 284 
[16] and with monodentate P-stereogenic phosphanes [26]. Gavrilov [7e11,27] has applied libraries of 285 
bidentate P-stereogenic diamidophosphite ligands with 1,3,2-dizaphospholidine rings as terminal 286 
fragments and several diol-derived bridging fragments to the palladium-catalyzed asymmetric allylic 287 
alkylation process, achieving lower activity and better enantioselectivity than those described in this 288 
paper. The presence of the stereogenic phosphorous atom included in a rigid cycle attached to the 289 
metallic center may enhance the enantioselectivity of the catalytic systems. 290 
Considering that some reports [18,28,29] describe that different counterions can affect the activity and 291 
enantioselectivity of the process, we compared the results obtained in the allylic alkylation reaction with 292 
complexes 2 and 3, which contain the hexafluorophosphate and tetraphenylborate respectively. In 293 
particular, comparing the results with the pair of complexes 2a-(S,S;Sal,Sal;S,S) and 3a-294 
(S,S;Sal,Sal;S,S) better activity and enantioselectivity was obtained in the presence of the BPh4    anion 295 
(entry 2 vs. 4) but the  opposite was observed with precursors 2b-(R,R;Ral,Ral;R,R) and 3b- 296 
(R,R;Ral,Ral;R,R) (entries 6 and 7). Literature concerned with anion effects in homogeneous catalysis 297 
suggests that larger boron anions can sometimes afford faster reactions [18]. Pregosin and coworkers 298 
[28] describe a substantial amount of ion pairing in dichlorometane solution and that the external BPh4 299 
   anion tends to be located in a remote position with respect the coordinated allyl ligand, so it is not 300 
surprising to find different anion effects between complexes containing different bisdiamidophosphite 301 
ligands. 302 
We also tested the catalytic behaviour of the preformed complexes 2 and 3 in the allylic amination of 303 
rac-I using benzylamine as nucleophile. The results obtained are shown in Table 2. Similar or better 304 
activity is obtained in the amination than in the alkylation process with all the precursors except for 2a-305 
(R,R;Sal,Sal;R,R) and 2b. Regarding the enantioselectivity, with complexes with diamidophosphites a 306 
and c similar or lower ee values are obtained respect to the alkylation process while those precursors 307 
with b  ligand similar or higher values were found.  308 
In general terms it can concluded that precursors with the BPh4    anion lead to better activities and that 309 
the best catalytic performance is obtained with 3a complexes in both alkylation and amination reactions. 310 
It is important to recall that the absolute configuration of the amination product with precursors 311 
containing ligands a and b is the same as for the alkylation reaction, although the CIP descriptor is 312 
inverted because of the change in the priority of the groups. However, in the case of the precursor 2c-313 
(R,R;Sal;R,R) there is a change in the sense of the asymmetric induction between alkylation and 314 
amination (entry 7). This result is unexpected but has already been reported with phosphite [4c], 315 
phosphoramidite [30], diphosphine [31], and also diamidophosphite ligands. [7a,16]. 316 
Due to the low enantioselectivies attained in the alkylation process with monodentate diamidophosphite 317 
ligands, the study of the amination reaction with these precursors was not performed. 318 
Complexes 2a and 2c were tested as catalyitic precursors using the cyclic substrate rac-3-acetoxy-1-319 
cyclohexene (rac-IV), which is usually used as a model cyclic substrate, under the same conditions 320 
described above for the open acetate rac-I (Scheme 4). 321 
The catalytic systems are less active and selective with the cyclic rac-IV substrate than with the model 322 
rac-I one in this process, achieving lower conversions and enantioselectivities.  323 
 324 
2.6. Synthesis and characterization of cationic allylpalladium complexes [Pd(h3-(1,3-Ph2-C3H3)(P-P)]X 325 
The Pd-catalyzed enantioselective nucleophilic substitution of rac-3-acetoxy-1,3-diphenyl-1-propene 326 
proceed via a cationic intermediate [Pd(h3-(1,3-Ph2-C3H3)(P-P)]þ. 327 
As methallyl palladium complexes containing ligand a showed the best catalytic performance and ligand 328 
b showed the lowest selectivity out of all the complexes reported here, we prepared and characterized 329 
the putative diphenylallyl intermediates 6b and 7a (Scheme 5) to rationalize the catalytic results. 330 
31P{1H} NMR spectra showed two sharp doublets with an AB pattern, revealing two different and 331 
strongly coupled phosphorus atoms (2J ¼ 140e152 Hz), indicating once again the loss of C2 symmetry 332 
of the bis(diamidophosphite) ligands in the allylic palladium complex. 333 
The 1H NMR spectra of complexes 6b-(R,R;Ral,Ral;R,R) and 7a- (R,R;Sal,Sal;R,R) indicated the 334 
presence of only one species. Two different signals for the two terminal allylic protons appeared. A syn-335 
syn configuration is suggested according to the NOESY experiments and to the triplet shown in the 1H 336 
NMR spectra for the central allylic hydrogen with coupling constants value of 12.9 Hz Hcentral-Hanti 337 
very similar to those described in the literature [32]. 13C NMR spectra showed that the chemical shift 338 
values of the two allylic terminal carbon atoms are substantially different compared to those observed 339 
for the parent methylallyl complexes 2a- (R,R;Sal,Sal;R,R) and 2b-(R,R;Ral,Ral;R,R) (92.3 and 85.4 for 340 
b, 93.7  and 82.6 for 7a). It is reported [33] that the difference between the chemical shifts of the two 341 
allylic terminal carbon atoms is a useful tool to evaluate the asymmetry of the allyl bonding. The larger 342 
difference observed for 2a is in good agreement with its better enantioselectivity in the alkylation 343 
process 344 
  345 
3. CONCLUSIONS 346 
 347 
Cationic allylic complexes [Pd(h3-2-CH3-C3H4)(P-P)]X (X ¼ PF6, BPh4) with both diastereoisomers 348 
of monodentate and bidentate diamidophosphite ligands a-f, based on disubstituted cyclohexane 349 
diamine, have been prepared and fully characterized. The X-ray structure for complex 2e-350 
(R,R;Ral,Ral;R,R) suggests a partial multiple-bond character for thee P-N bond. The new complexes 351 
have been used as catalytic precursors in the allylic alkylation and amination reaction of the model 352 
substrate rac-3-acetoxy-1,3- diphenyl-1-propene showing good activity except for complexes containing 353 
the (R,R)-N,N’-dimethyl-cyclohexane-1,2-diamine terminal fragment that resulted inactive in the 354 
process. The best asymmetric induction has been achieved using 3a-(S,S;Sal,Sal;S,S) and 3a-355 
(R,R;Ral,Ral;R,R) enantiomeric complexes as precursors leading to very similar activity (100%) and 356 
good ee values for alkylation (84%) and for amination (80%) reactions. The results obtained indicate 357 
that the presence of the different anions (PF6   , BPh4   ) influence both the activity and the 358 
enantioselectivity of the process. A marked match-mismatch effect has been observed for both 359 
diastereoisomers of complexes containing ligands b and c with a long bridging fragment. The absolute 360 
configuration of the major product depends on the configuration of the cyclohexyldiamine-derived 361 
terminal fragment when the bridge is flexible (ligands a and b), while with the more rigid bridging 362 
fragment (ligand d) it is the configuration of the binaphtholderived bridge that dictates the product 363 
configuration. These results allow us to conclude that for precursors containing bidentate 364 
diamidophopsphite ligands derived from disubstituted N,N’-cyclohexane-1,2-diamine the presence of 365 
the benzyl substituent and the short and flexible butanodiol-derived bridging fragment leads to the most 366 
efficient catalytic precursors in the allylic substitution reaction with the model substrate. 367 
  368 
4. Experimental 369 
 370 
4.1. General information 371 
All manipulations were performed under a dry nitrogen atmosphere using standard vacuum-line Schlenk 372 
techniques. Anhydrous dichloromethane, tetrahydrofuran and toluene were obtained from a solvent 373 
purification system. NEt3 was distilled from CaH2 and collected over 4 Å molecular sieves before use. 374 
The diols, (S,S)-2,3- butanediol, (4R,5R) and (4S,5S) -4,5-di(hydroxymethyl)-2,2- dimethyl-1,3-375 
dioxolane, (R)- and (S)-1,1’-bi-2-naphthol, (R)- and (S)-N,N’-dimethyl-1,1’-binaphthyl-2,2’-diamine 376 
and PCl3 were used as supplied. The dimeric palladium complex [Pd(h3-2-Me-C3H4)(m- Cl)]2 was 377 
prepared as described in the literature [34]. Bis(diamidophosphite) ligands a-(R,R;Ral,Ral;R,R), a-378 
(R,R;Sal,Sal;R,R), b-(R,R;Ral,Ral;R,R), c-(R,R;Sal;R,R), d-(R,R;Ral,Ral;R,R), e-(R,R;Ral,Ral;R,R), as 379 
well as monodentate diamidophosphite ligands f-(R,R;Ral), f- (S,S;Ral) and g-(R,R;Sal) were prepared 380 
as previously described by us [15,16]. 1H and 13C (standard SiMe4), and 31P (standard H3PO4) NMR 381 
spectra were recorded on 400 MHz or 500 MHz spectrometers. High-resolution mass spectra were 382 
obtained on a time-of-flight instrument using electrospray ionization. 383 
 384 
4.2. Synthesis of ligands 385 
4.2.1. Synthesis of bis(diamidophosphite) ligands a-(S,S;Sal,Sal;S,S), b-(R,R;Sal,Sal;R,R) and c-386 
(R,R;Ral;R,R) 387 
(R,R)-N,N’-dibenzyl-1,2-cyclohexanediamine (1.06 g, 3.6 mmol) and NEt3 (1.50 mL, 10.8 mmol) were 388 
dissolved in 10 mL of toluene. PCl3 (0.40 mL, 4.6 mmol) dissolved in 5 mL of toluene was added drop 389 
 wise at 0 C. The mixture was allowed to warm up to room temperature and was stirred for 2 h. The 390 
formation of the chlorodiazaphospholidine was monitored by 31P NMR spectroscopy (d ¼ 174.5 ppm) 391 
being complete after this period. The solvent and the excess of PCl3 were thoroughly removed under 392 
reduced pressure to afford a viscous oil. This oil was dissolved in toluene (10 mL) and 1.3 mL of NEt3 393 
was added. The corresponding diol (1.8 mmol), ((S,S)-2,3-butanediol in toluene (10 mL), (4S,5S)-4,5- 394 
di(hydroxymethyl)-2,2-dimethyl-1,3-dioxolane and (R)-1,1’-bi-2- naphthol in THF (10 mL)) was added 395 
 dropwise at 0 C. After 4 h of stirring, the white precipitate of triethylamine hydrochloride was filtered 396 
off. The solvent was removed in vacuum and a yellowish oil was obtained and used without purification. 397 
 398 
a-(S,S;Sal,Sal;S,S) 399 
 Yield: 970 mg (73%). [a]298 ¼ þ37.60  (c 1.0, CH2Cl2). 31P {1H} (CDCl3, 121,44 MHz), 1H NMR 400 
(CDCl3, 400 MHz) and 13C NMR (CDCl3, 100.6 MHz) were described for the enantiomer a-(R,R;Ral,- 401 
Ral;R,R) in previous work [15]. 402 
 403 
b-(R,R;Sal,Sal;R,R) 404 
Yield: 594 mg (41%). [a]298 ¼ -  44.00  (c 1.0, CH2Cl2). 31P{1H} NMR (101.25 MHz, CDCl3, d 405 
(ppm), J (Hz)): 136.3 (s). 1H NMR (400 MHz, CDCl3, d (ppm), J (Hz)): 7.43e7.11 (om, 32H, CH(Ar)), 406 
4.38e4.17 (om, 6H, CH2(Bn)) 3.96e3.86 (om, 4H, 2CH2(Bn) þ 2OCH2), 3.84 (m, 2H, OCH), 3.56 (m, 407 
2H, OCH2), 3.01 (m, 2H, CH(Cy)), 2.55 (m, 2H, CH(Cy)), 2.00e0.85 (om, 16H, CH2(Cy)), 1.39 (s, 6H, 408 
CH3). 13C{1H} NMR (100.0 MHz, CDCl3, d (ppm), J (Hz)): 140.9 (d, 3JCP ¼ 6.0, 2C, C(Ar)), 140.5 409 
(d, 3JCP ¼ 3.0, 2C, C(Ar)), 129.0e125.0 (m, 20C, CH(Ar)), 109.4 (s, 1C, O2CMe2), 78.3 (d, 3JCP ¼ 410 
3.0, 2C, OCH), 67.3 (d, 2JCP ¼ 7.0, 2C, CH(Cy)), 66.4 (d, 2JCP ¼ 8.0, 2C, CH(Cy)), 64.6 (d, 2JCP ¼ 411 
9.0, 2C, OCH2), 50.1 (d, 2JCP ¼ 33.0, 2C, CH2(Bn)), 48.2 (d, 2JCP ¼ 14.0, 2C, CH2(Bn)), 30.3 (s, 2C, 412 
CH2(Cy)), 29.9 (s, 2C, CH2(Cy)), 27.1 (s, 2C, CH2(Cy)), 24.5 (s, 2C, CH2(Cy)), 24.2 (s, 2C, 413 
CH2(Cy)). HR-MS (ESI, m/z): calcd for C47H60N4O4P2 806.4090, found 807.4145 [MH]þ. 414 
 415 
c-(R,R;Ral;R,R) 416 
Yield: 435 mg (26%). [a]298 ¼ -  41.55  (c 1.0, CH2Cl2). 31P{1H} NMR (101.25 MHz, CDCl3, d 417 
(ppm), J (Hz)): 139.2 (s). 1H NMR (400 MHz, C6D6, d (ppm), J (Hz)): 7.90e6.95 (om, 32H, CH(Ar)), 418 
4.39e4.13 (om, 4H, CH2(Bn)) 3.80e3.66 (om, 2H, CH2(Bn)), 3.15 (dd, 2JHH ¼ 15.8, 3JHP ¼ 7.2, 2H, 419 
CH2(Bn)), 2.83 (m, 2H, CH(Cy)), 2.46 (m, 2H, CH(Cy)), 1.68e0.53 (om, 16H, CH2(Cy)). 13C{1H} 420 
NMR (100.0 MHz, C6D6, d (ppm), J (Hz)): 152.2 (d, 3JCP ¼ 5.0, 2C, C(Ar)), 141.7 (d, 2JCP ¼ 12.0, 421 
2C, C(Ar)), 140.7 (d, 3JCP ¼ 4.0, 2C, C(Ar)), 135.1 (s, 2C, C(Ar)), 134.1 (s, 2C, C(Ar)), 130.4 (s, 2C, 422 
C(Ar)), 129.1e121.4 (om, 32C, CH(Ar)), 67.6 (d, 2JCP ¼ 7.0, 2C, CH(Cy)), 66.6 (d, 2JCP ¼ 7.0, 2C, 423 
CH(Cy)), 50.3 (d, 2JCP ¼ 33.0, 2C, CH2(Bn)), 48.4 (d, 2JCP ¼ 14.0, 2C, CH2(Bn)), 30.8 (d, 3JCP ¼ 424 
3.0, 2C, CH2(Cy)), 30.6 (s, 2C, CH2(Cy)), 24.5 (s, 2C, CH2(Cy)), 24.3 (s, 2C, CH2(Cy)). HR-MS (ESI, 425 
m/z): calcd for C60H60N4O2P2 930.4192, found 931.4267 [MH]þ. 426 
 427 
4.2.2. Synthesis of bis(diamidophosphite) ligand e-(R,R;Ral,Ral;R,R) 428 
(R,R)-N,N’-dimethylcyclohexane-1,2-diamine (0.51 g, 3.6 mmol) and NEt3 (1.50 mL, 10.8 mmol) were 429 
dissolved in 10 mL of toluene. PCl3 (0.4 mL, 4.6 mmol) dissolved in 5 mL of toluene was added 430 
 dropwise at 0 C. The mixture was allowed to warm up to room temperature and was stirred for 2 h. 431 
The formation of the chlorodiazaphospholidine was monitored by phosphorus NMR spectroscopy (d ¼ 432 
175.4 ppm) being complete after this period. The solvent and the excess of PCl3 were thoroughly 433 
removed under reduced pressure to afford an oil. This oil was dissolved in toluene (10 mL) and DMAP 434 
 (2.6  1  0 3 g, 0.021 mmol) was added. A solution of the stoichiometric amount of the diol (R,R)-2,3-435 
butanediol (0.16 g, 1.8 mmol) and 1,3mL de NEt3 (9.0 mmol) in toluene (10 mL) was added dropwise 436 
 in three portions at 0 C. After stirring overnight at room temperature, hexane (5 mL)was added and the 437 
white precipitate of triethylamine hydrochloride was filtered off. The solvent was removed in vacuum 438 
and a brownish oil was obtained and used without further purification. 439 
 440 
Yield: 349 mg (45%); [a]298 ¼ -  143.63  (c 1.0, CH2Cl2). 31P{1H} NMR (101.25 MHz, CDCl3, d 441 
(ppm), J (Hz)): 142.6 (s). 1H NMR (300 MHz, CD2Cl2, d (ppm), J (Hz)): 4.00 (m, 2H, OCH), 2.69 (d, 442 
3JHP ¼ 13.5 6H, CH3(NMe)), 2.53 (d, 3JHP ¼ 14.2, 6H, CH3(NMe)), 2.04 (m, 2H, CH(Cy)), 1.78 (m, 443 
2H, CH(Cy)), 1.42e0.94 (om, 16H, 16CH2(Cy)), 1.11 (d, 3JHH ¼ 6.2, 6H, CH3). 13C{1H} NMR 444 
(100.0 MHz, CDCl3, d (ppm), J (Hz)): 72.6 (dd, 2JCP ¼ 12.0, 3JCP ¼ 1.0, 2C, OCH), 69.3 (d, 2JCP ¼ 445 
6.0, 2C, CH(Cy)), 66.0 (d, 2JCP ¼ 9.0, 2C, CH(Cy)), 33.1 (d, 2JCP ¼ 36.0, 2C, CH3(NMe)), 30.2 (d, 446 
2JCP ¼ 11.0, 2C, CH3(NMe)), 29.5 (s, 2C, CH2(Cy)), 29,1 (d, 3JCP ¼ 4.0, 2C, CH2(Cy)), 24.3 (s, 2C, 447 
CH2(Cy)), 24.2 (s, 2C, CH2(Cy)), 16.3 (d, 3JCP ¼ 3.0, 2C, CH3). HR-MS (ESI, m/z): calcd for 448 
C20H40N4O2P2 430.2626, found 431.2694 [MH]þ. 449 
 450 
4.3. Synthesis of palladium complexes 451 
4.3.1. Synthesis of [PdCl2P2] 1a and 1c 452 
To a solution of 155 mg (0.50 mmol) of [PdCl2(COD)] in 10 mL of  toluene at 0 C, a solution of 0.50 453 
mmol of the corresponding diamidophosphite ligand (a-(S,S;Sal,Sal;S,S) or c-(R,R;Sal;R,R)) in 10 Ml 454 
of CH2Cl2 was added. After 3 h stirring at room temperature, the resulting yellow solution was 455 
concentrated under vacuum and 10 mL of ether were added. The yellow precipitate was filtered and 456 
dried. 457 
 458 
1a-(S,S;Sal,Sal;S,S) 459 
Yield: 169 mg (37%). Mp  : 192e202 C dec. 31P{1H} NMR (101.25 MHz, CDCl3, d (ppm), J (Hz)): 460 
111.4 (s). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 7.57e7.00 (om, 20H, CH(Ar)), 5.11 (pt, 2JHH 461 
¼ 3JHP ¼ 7.0, 1H, CH2(Bn)), 5.08 (pt, 2JHH ¼ 3JHP ¼ 7.0, 1H, CH2(Bn)), 4.64e4.50 (om, 4H, 462 
CH2(Bn)), 4.22 (pt, 2JHH ¼ 3JHP ¼ 5.9, 1H, CH2(Bn)), 4.19 (pt, 2JHH ¼ 3JHP ¼ 5.5, 1H, 1H, 463 
CH2(Bn)), 3.96 (m, 2H, OCH), 3.50 (m, 2H, CH(Cy)), 3.20 (m, 2H, CH(Cy)),1.90e0.81 (om, 16H, 464 
CH2(Cy), 0.84 (d, 3JHH ¼ 5.0, 6H, CH3). 13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J (Hz)): 140.7 465 
(pt, 3JCP ¼ 2.5, 2C, C(Ar)), 140.3 (pt, 3JCP ¼ 1.9, 2C, C(Ar)), 129.4e126.2 (20C, CH(Ar)), 80.6 (pt, 466 
2JCP ¼ 3JCP ¼ 5.0, 2C, OCH), 69.6 (bs, 2C, CH(Cy)), 65.6 (bs, 2C, CH(Cy)), 50.2 (pt, JCP ¼ 6.8, 2C, 467 
CH2(Bn)), 48.5 (pt, 2JCP ¼ 7.8, 2C, CH2(Bn)), 30.5 (bs, 2C, CH2(Cy)), 27.9 (bs, 2C, CH2(Cy)), 24.6 468 
(bs, 2C, CH2(Cy)), 23.5 (bs, 2C, CH2(Cy)), 17.9 (pt, JCP ¼ 2.2, 2C, CH3). HR-MS (ESI, m/z): calcd 469 
for C44H56Cl2N4O2P2Pd 910.2290, found 875.2640 [M-Cl]þ. Anal. Calcd. for 470 
C44H56Cl2N4O2P2Pd: C 57.93, H 6.19, N 6.14%; found: C 56.71, H 6.85, N 6.44%. 471 
 472 
1c-(R,R;Sal;R,R) 473 
 Yield: 177 mg (32%). Mp: 230e234 C dec. 31P{1H} NMR (121.4 MHz, Toluene/CH2Cl2, d (ppm), J 474 
(Hz)): 101.7 (s). 1H NMR (400 MHz, CDCl3, d (ppm), J (Hz)): 8.08e6.83 (om, 32H, CH(Ar)), 5.56 (pt, 475 
2JHH ¼ 3JHP ¼ 8.1, 2H, CH2(Bn)), 5.52 (pt, 2JHH ¼ 3JHP ¼ 7.8, 1H, CH2(Bn)), 4.47 (d, 2JHH ¼ 476 
17.6, 1H, CH2(Bn)), 3.46e3.26 (om, 4H, 2CH(Cy) þ 2CH2(Bn)), 3.02 (d, 2JHH ¼ 16.6, 2H, CH2(Bn)), 477 
2.89 (m, 2H, CH(Cy)), 1.85e0.68 (ms, 16H, CH2(Cy). 13C{1H} NMR (100.6 MHz, CDCl3, d (ppm), J 478 
(Hz)): 147.6 (pt, 2JCP ¼ 6.3, 2C, OC(Ar)), 140.0 (pt, 3JCP ¼ 4.0, 2C, C(Ar)), 138.2 (pt, 3JCP ¼ 3.5, 479 
2C, C(Ar)), 133.7 (s, 2C, C(Ar)), 131.0e119.5 (36C, 32CH(Ar) þ 4C(Ar), 71.5 (bs, 2C, CH(Cy)), 64,7 480 
(bs, 2C, CH(Cy)), 53.0 (d, JCP ¼ 7.0, 2C, CH2(Bn)), 46.4 (pt, JCP ¼ 5.4, 2C, CH2(Bn)), 31.2 (bs, 2C, 481 
CH2(Cy)), 29.2 (bs, 2C, CH2(Cy)), 23.9 (bs, 2C, CH2(Cy)), 23.7 (bs, 2C, CH2(Cy)). MALDI-TOF-MS 482 
(m/z): calcd for C60H60Cl2N4O2P2Pd 1106.2603, found 1036.3 [M-2Cl]þ. 483 
 484 
4.3.2. Synthesis of [Pd(h3-2-Me-C3H4)(P-P]PF6 (2a, 2b, 2c and 2e) 485 
To a solution of the appropriate ligand (0.40 mmol) in toluene  (10 mL) at 0 C a solution of [Pd(h3-2-486 
Me-C3H4)(m-Cl)]2 (79 mg, 0.20 mmol) in CH2Cl2 (5 mL) was added dropwise. Then a solution of 487 
NaPF6 (67 mg, 0.40 mmol) in THF (5 mL) was added. After 3 h of stirring at room temperature, the 488 
solution was washed with  deoxygenated water (2  4 mL). The organic phase was dried over anhydrous 489 
Na2SO4, filtered off and the solvent removed under reduced pressure. The white or yellow solid 490 
obtained was washed several times with diethyl ether or n-pentane and dried under reduced pressure. 491 
 492 
2a-(R,R;Sal,Sal;R,R) 493 
 Yield: 246 mg (59%). Mp: 135e148 C dec. 31P{1H} NMR (121.2 MHz, CDCl3, d (ppm), J (Hz)): 494 
134.7 (d, 2JPP ¼ 95.4), 132.6 (d, 2JPP ¼ 95.4). 1H NMR (500 MHz, CD2Cl2, d (ppm), J (Hz)): 495 
7.41e7.05 (om, 20H, CH(Ar)), 4.59 (pt, 2JHH ¼ 3JHP ¼ 16.0 1H, CH2(Bn)), 4.44e4.20 (om, 7H, 496 
5CH2(Bn) þ 2OCH), 4.07 (m, 2H, 2CH2(syn)), 3.92 (dd, 2JHH ¼ 15.0 3JHP ¼ 10.0, 1H, CH2(Bn)), 497 
3.80 (dd, 2JHH ¼ 15.0 3JHP ¼ 7.0, 1H, CH2(Bn)), 3.00 (m, 1H, CH(Cy)), 2.91 (m, 1H, CH(Cy)), 2.85 498 
(m, 2H, CH(Cy)), 2.52 (d, 2JHP ¼ 15.0, 1H, CH2(anti)), 2.23 (d, 2JHP ¼ 15.0,1H, CH2(anti)), 499 
2.15e1.05 (om, 16H, CH2(Cy)), 1.42 (s, 3H, CH3(allyl)), 1.20 (d, 3JHH ¼ 6.0, 3H, CH3), 1.13 (d, 3JHH 500 
¼ 6.5, 3H, CH3). 13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J (Hz)): 139.4 (pt, JCP ¼ 8.8 1C, 501 
C(allyl)), 138.4 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 138.3 (d, 3JCP ¼ 3.8, 1C, C(Ar)), 137.8 (d, 3JCP ¼ 5.0, 1C, 502 
C(Ar)), 137.6 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 129.0e127.5 (20C, CH(Ar)), 79.8 (dd, 2JCP ¼ 34.4 3JCP ¼ 503 
12.0, 1C, OCH), 76,7 (dd, 2JCP ¼ 31.2, 3JCP ¼ 10.0, 1C, OCH), 70.4 (dd, 2JCPtrans ¼ 42.5, 2JCPcis 504 
¼ 5.0, 1C, CH2(allyl)), 69.4 (dd, 2JCPtrans ¼ 42.5, 2JCPcis ¼ 5.0, 1C, CH2(allyl)), 67.7 (d, 2JCP ¼ 505 
3.8, 1C, CH(Cy)), 67.5 (d, 2JCP ¼ 3.8, 1C, CH(Cy)), 65.5 (d, 2JCP ¼ 5.0, 1C, CH(Cy)), 65.3 (d, 2JCP 506 
¼ 5.0, 1C, CH(Cy)), 51.2 (d, 2JCP ¼ 18.8, 1C, CH2(Bn)), 50.3 (d, 2JCP ¼ 17.5, 1C, CH2(Bn)), 48.0 (d, 507 
2JCP ¼ 7.5, 1C, CH2(Bn)), 47.7 (d, 2JCP ¼ 8.8, 1C, CH2(Bn)), 30.3 (d, 3JCP ¼ 1.3, 1C, CH2(Cy)), 508 
30.1 (d, 3JCP ¼ 1.3, 1C, CH2(Cy)), 29.8 (s, 1C, CH2(Cy)), 29.7 (s, 1C, CH2(Cy)), 29.6 (s, 1C, 509 
CH2(Cy)), 29.5 (s, 1C, CH2(Cy)), 24.2 (d, 3JCP ¼ 7.5, 1C, CH2(Cy)), 23.9 (d, 3JCP ¼ 6.3 1C, 510 
CH2(Cy)), 23.4 (s, 1C, CH3(allyl)), 18.1 (d, 3JCP ¼ 1.3, 1C, CH3), 18.0 (d, 3JCP ¼ 1.3, 1C, CH3). 511 
HR-MS (ESI, m/z): calcd for C48H63N4O2P2Pd 895.3461, found 895.3460 [M]þ. Anal. Calc. for 512 
C48H63F6N4O2P3Pd: C 55.36, H 6.10, N 5.38%; found: C 55.11, H 6.26, N 5.46%. 513 
 514 
2a-(S,S;Sal,Sal;S,S) 515 
 Yield: 104 mg (25%). Mp: 168e178 C dec. 31P NMR (101.2 MHz, CDCl3, d (ppm), J (Hz)): 135.2 (d, 516 
2JPP ¼ 83.2),130.7 (d, 2JPP ¼ 83.2). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 7.87e7.05 (om, 517 
20H, CH(Ar)), 4.50 (pt, 2JHH ¼ 3JHP ¼ 15.0, 1H, CH2(Bn)), 4.38e3.81 (om, 8H, 6CH2(Bn) þ 2OCH), 518 
4.29 (bs, 2H, CH2(syn)), 4.23 (bs, 2H, CH2(syn)), 3.65 (dd, 2JHH ¼ 15.0, 3JHP ¼ 5.0, 1H, CH2(Bn)), 519 
3.15e2.85 (om, 4H, 4CH(Cy)), 2.92 (d, 2JHP ¼ 15.0,1H, CH2(anti)), 2.69 (d, 2JHP ¼ 10.0, 1H, 520 
CH2(anti)), 2.20e1.06 (ms, 16H, CH2(Cy)), 1.62 (s, 3H, CH3(allyl), 1.20 (d, 3JHH ¼ 6.5, 3H, CH3), 521 
1.16 (d, 3JHH ¼ 6.5, 3H, CH3). 13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J (Hz)): 140.2 (pt, JCP 522 
¼ 7.5, 1C, C(allyl)), 138.9 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 138.7 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 138.5 (d, 3JCP 523 
¼ 10.0, 1C, C(Ar)), 138.4 (d, 3JCP ¼ 8.8, 1C, C(Ar)), 129.2e126.7 (20C, CH(Ar)), 79.1 (pt, JCP ¼ 4.4, 524 
1C, OCH), 78.1 (dd, 525 
 526 
2c-(R,R;Ral;R,R) 527 
Yield: 208 mg (42%).  Mp: 191e197 C dec. 31P NMR (101.2 MHz, CDCl3, 298 K, d (ppm), J (Hz)): 528 
138.4 (d, 2JPP ¼ 59.9), 133.4 (d, 2JPP ¼ 59.9). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 529 
8.20e6.53 (om, 32H, CH(Ar)), 4.74 (pt, 2JHH ¼ 3JHP ¼ 16.0, 1H, CH2(Bn)), 4.50 (bs, 1H, CH2(syn)), 530 
4.44 (bs, 1H, CH2(syn)), 4.38e3.77 (om, 3H, CH2(Bn)), 3.38 (d, 2JHP ¼ 10.0, 1H, CH2(anti)), 3.26 (m, 531 
1H, CH(Cy)), 3.11 (m, 1H, CH(Cy)), 3.05e2.95 (om, 2H, 1CH2(anti) þ 1CH2(Bn)), 2.94 (dd, 2JHH ¼ 532 
16.0, 3JHP ¼ 9.5, 1H, CH2(Bn)), 2.82e2.65 (om, 2H, 1CH2(Bn) þ 1CH(Cy)), 2.60e2.50 (om, 2H, 533 
1CH2(Bn) þ 1CH(Cy)), 2.13e0.25 (om, 16H, CH2(Cy)), 1.76 (s, 3H, CH3(allyl) þ 3CH3(allyl)). 534 
13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J (Hz)): 152.8 (s, 1C, C(Ar)), 147.3 (d, 2JCP ¼ 3.8, 1C, 535 
C(Ar)), 147.1 (d, 2JCP ¼ 5.0, 1C, C(Ar)), 139.7 (pt, JCP ¼ 7.5, 1C, C(allyl)), 138.4 (d, 3JCP ¼ 3.8, 1C, 536 
C(Ar)), 138.3 (d, 3JCP ¼ 7.5, 1C, C(Ar)), 137.5 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 136.6 (d, 3JCP ¼ 5.0, 1C, 537 
C(Ar)), 133.6e121.5 (37C, 5C(Ar) þ 32CH(Ar)), 76.6 (d, 2JCPtrans ¼ 35.0, 1C, CH2(allyl)), 74.2 (d, 538 
2JCPtrans ¼ 36.3, 1C, CH2(allyl)), 66.2 (d, 2JCP ¼ 3.8, 1C, CH(Cy)), 65.9 (bs, 1C, CH(Cy)), 65.8 (d, 539 
2JCP ¼ 2.5, 1C, CH(Cy)), 64.3 (bs, 1C, CH(Cy)), 49.1 (d, 2JCP ¼ 11.3, 1C, CH2(Bn)), 48.5 (d, 2JCP ¼ 540 
15.0, 1C, CH2(Bn)), 46.5 (d, 2JCP ¼ 18.8, 1C, CH2(Bn)), 46.1 (d, 2JCP ¼ 18.8, 1C, CH2(Bn)), 29.9 (d, 541 
3JCP ¼ 6.3, 1C, CH2(Cy)), 29.7 (s, 1C, CH2(Cy)), 29.5 (d, 3JCP ¼ 6.3, 1C, CH2(Cy)), 28.8 (s, 1C, 542 
CH2(Cy)), 24.3 (d, 3JCP ¼ 11.3, 1C, CH2(Cy)), 24.0 (s, 1C, CH2(Cy)), 23.7 (s, 1C, CH2(Cy)), 23.5 (s, 543 
1C, CH2(Cy)), 23.2 (s, 1C, CH3(allyl)). HR-MS (ESI, m/z): calcd for C64H67N4O2P2Pd 1091.3774, 544 
found 1091.3779 [M]þ. 545 
 546 
2c-(R,R;Sal;R,R) 547 
 Yield: 203 mg (41%). Mp: 196e202 C dec. 31P NMR (101.25 MHz, CDCl3, 298 K, d (ppm), J (Hz)): 548 
139.0 (d, 2JPP ¼ 60.1), 133.0 (d, 2JPP ¼ 60.1). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 549 
8.11e6.56 (om, 32H, CH(Ar)), 4.80 (pt, 2JHH ¼ 3JHP ¼ 16.0, 1H, CH2(Bn)), 4.58 (bs, 1H, CH2(syn)), 550 
4.47 (bs, 1H, CH2(syn)), 4.36e4.17 (om, 2H, CH2(Bn)), 3.85 (dd, 2JHH ¼ 15.0, 3JHP ¼ 5.0, 1H, 551 
CH2(Bn)), 3.30 (d, 2JHP ¼ 10.0, 1H, CH2(anti)), 3.02e2.77 (om, 4H, CH(Cy)), 2.75e2.61 (om, 2H, 552 
CH2(Bn)) 2.71 (bs,1H, CH2(anti)), 2.50 (dd, 2JHH ¼ 15.5, 3JHP ¼ 10.0, 1H, CH2(Bn)), 2.22 (dd, 553 
2JHH ¼ 15.0, 3JHP ¼ 5.0, 1H, CH2(Bn)), 1.93 (s, 3H, CH3(allyl)), 1.91e0.68 (om, 16H, CH2(Cy). 554 
13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J (Hz)): 153.6 (s, 1C, C(Ar)), 152.8 (s, 1C, C(Ar)), 146.7 555 
(d, 2JCP ¼ 5.0, 1C, C(Ar)), 146.5 (d, 2JCP ¼ 7.5, 1C, C(Ar)), 140.3 (pt, JCP ¼ 7,5, 1C, C(allyl)), 138.9 556 
(d, 3JCP ¼ 6.3, 1C, C(Ar)), 138.2 (d, 3JCP ¼ 3.8, 1C, C(Ar)), 138.2 (d, 3JCP ¼ 2.5, 1C, C(Ar)), 138.1 557 
(d, 3JCP ¼ 3.8, 1C, C(Ar)), 133.8 (s, 1C, C(Ar)), 131.2 (s, 1C, C(Ar)), 130.7 (s, 1C, C(Ar)), 130.3 (s, 558 
1C, C(Ar)), 128.8e125.7 (32C, CH(Ar)), 76.3 (d, 2JCPtrans ¼ 37.5, 1C, CH2(allyl)), 73.7 (d, 2JCPtrans 559 
¼ 37.5, 1C, CH2(allyl)), 70.5 (d, 2JCP ¼ 2.5, 1C, CH(Cy)), 68,9 (s, 1C, CH(Cy)), 66.2 (d, 2JCP. ¼1.3, 560 
1C, CH(Cy)), 66.3 (d, 2JCP ¼ 1.3, 1C, CH(Cy)), 53.0 (d, 2JCP ¼ 22.5, 1C, CH2(Bn)), 50.0 (d, 2JCP ¼ 561 
18.8, 1C, CH2(Bn)), 46.6 (d, 2JCP ¼ 7.5, 1C, CH2(Bn)), 46.1 (d, 2JCP ¼ 8.8, 1C, CH2(Bn)), 31.3 (d, 562 
3JCP ¼ 2.5, 1C, CH2(Cy)), 30.9 (d, 3JCP ¼ 2.5, 1C, CH2(Cy)), 30.3 (d, 3JCP ¼ 8.8, 1C, CH2(Cy)), 563 
30.1 (d, 3JCP ¼ 8.8, 1C, CH2(Cy)), 23.9 (s, 3C, CH2(Cy)), 23.65 (s, 1C, CH2(Cy)), 23.0 (s, 1C, 564 
CH3(allyl)). HR-MS (ESI, m/z): calcd for C64H67N4O2P2Pd 1091.3774, found 1091.3783 [M]þ. Anal. 565 
Calc. for C64H67F6N4O2P3Pd: C 62.11, H 5.46, N 4.53%; found: C 59.94, H 5.70, N 4.89%. 566 
 567 
2e-(R,R;Ral,Ral;R,R) 568 
Yield: 106 mg (36%).  Mp: 172e180 C dec. 31P{1H} NMR (101.2 MHZ, CDCl3, d (ppm), J (Hz)): 569 
131.6 (d, 2JPP ¼ 90.5), 128.7 (d, 2JPP ¼ 90.5). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 4.54 (m, 570 
1H, OCH), 4.33 (m, 1H, OCH), 4.00 (bs, 1H, CH2(syn)), 3.91 (dd, 2JHH ¼ 15.0, 3JHH ¼ 5.0, 1H, 571 
CH2(syn)), 3.20 (d, 2JHP ¼ 15.0, 1H, CH2(anti)), 3.02 (d, 2JHP ¼ 15.0, 1H, CH2(anti)), 2.83 (d, 3JHP 572 
¼ 15.3, 3H, CH3(NMe)), 2.80 (m, 2H, CH(Cy)), 2.74e2.41 (om, 2H, CH(Cy)), 2.66 (d, 3JHP ¼ 15.5, 573 
3H, CH3(NMe)), 2.65 (d, 3JHP ¼ 15.5, 3H, CH3(NMe)), 2.54 (d, 3JHP ¼ 15.5, 3H, CH3(NMe)), 574 
2.20e1.75 (om, 8H, CH2(Cy)), 1.85 (s, 3H, CH3(allyl), 1.62e0.99 (om, (8H, CH2(Cy)), 1.30 (d, 3JHH ¼ 575 
4.0, 3H, CH3), 1.29 (d, 3JHH ¼ 4.0, 3H, CH3). 13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J (Hz)): 576 
139.2 (pt, JCP ¼ 3.8, 1C, C(allyl)), 78.2 (t, 2JCP1 ¼ 2JCP2 ¼ 3.8, 1C, OCH), 77.3 (m, 1C, OCH), 70.7 577 
(dd, 2JCPtrans ¼ 41.3, 2JCPcis ¼ 5.0, 1C, CH2(allyl)), 69.9 (dd, 2JCPtrans ¼ 38.8, 2JCPcis ¼ 6.3, 1C, 578 
CH2(allyl)), 68.7 (d, 2JCP ¼ 1.3, 1C, CH(Cy)), 68.3 (d, 2JCP ¼ 1.3, 1C, CH(Cy)), 64.4 (d, 2JCP ¼ 5.0, 579 
2C, CH(Cy)), 32.6 (d, 2JCP ¼ 28.7, 1C, CH3(NMe), 32.3 (d, 2JCP ¼ 28.3, 1C, CH3(NMe), 29.3 (d,  580 
2JCP ¼ 4.2, 1C, CH3(NMe), 29.1 (d, 2JCP ¼ 4.2, 1C, CH3(NMe)), 28.6 (d, 3JCP ¼ 3.8, 2C, CH2(Cy)), 581 
28.2 (d, 3JCP ¼ 6.3, 1C, CH2(Cy)), 28.1 (d, 3JCP ¼ 6.3, 1C, CH2(Cy)), 24.3 (s, 1C, CH3(allyl)), 23.9 582 
(bs, 4C, CH2(Cy)), 19.7 (pt, 2JCP ¼ 3JCP ¼ 2.5, 1C, CH3), 19.6 (pt, 2JCP ¼ 3JCP ¼ 2.5, 1C, CH3). 583 
HR-MS (ESI, m/z): calcd for C24H47N4O2P2Pd 591.2209, found 591.2207 [M]þ. 584 
 585 
4.3.3. Synthesis of [Pd(h3-2-Me-C3H4)(P-P]BPh4 (3a, 3b, 3d and 3e) 586 
To a solution of the corresponding diamidophosphite a, b, d, e  (0.40 mmol) in toluene (10 mL) at 0 C 587 
a solution of [Pd(h3-2-Me- C3H4)(m-Cl)]2 (79 mg, 0.20 mmol) in CH2Cl2 (5 mL) was added dropwise 588 
and then a solution of NaPF6 (67 mg, 0.40 mmol) in THF (5 mL). After 1 h of stirring at room 589 
temperature, a solution of NaBPh4 (204 mg, 0.60 mmol) in 20 mL of MeOH was added. The white solid 590 
formed on standing was filtered off and washed with deoxygenated water. 591 
 592 
3a-(R,R;Ral,Ral;R,R) 593 
 Yield: 173.0 mg (35%). Mp: 172e178 C dec. 31P NMR (101.2 MHz, CDCl3, 298 K, d (ppm), J (Hz)): 594 
135.6 (d, 2JPP ¼ 84.1), 130.7 (d, 2JPP ¼ 84.1). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 595 
7.64e6.74 (om, 40H, CH(Ar)), 4.37 (pt, 2JHH ¼ 3JHP ¼ 15.0, 1H, CH2(Bn)), 4.26 (pt, 2JHH ¼ 3JHP ¼ 596 
15.0, 1H, CH2(Bn)), 4.16e3.74 (om, 7H; 5H, CH2(Bn) þ 2H, OCH), 4.07 (om, 2H, CH2(syn)), 3.60 (dd, 597 
2JHH ¼ 16.0, 3JHP ¼ 6.0, 1H, CH2(Bn)), 3.10e2.97 (om, 2H, CH(Cy)), 2.86 (m, 1H, CH(Cy)), 2.79 598 
(m, 1H, CH(Cy)), 2.65 (d, 2JHP ¼ 10.0,1H, CH2(anti)), 2.52 (d, 2JHP ¼ 15.0, 1H, CH2(anti)), 599 
2.04e0.86 (om, 16H, CH2(Cy)), 1.48 (s, CH3(allyl)), 1.15 (d, 3JHH ¼ 6.2, CH3) 1.11 (d, 3JHH ¼ 6.0, 600 
CH3). 13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J (Hz)): 164.3 (q, 1JCB ¼ 49.0, 4C, CB(Ar)), 601 
140.1 (pt, JCP ¼ 7.5, 1C, C(allyl)), 138.4 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 138.4 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 602 
138.3 (d, 3JCP ¼ 10.0, 1C, C(Ar)), 138.2 (d, 3JCP ¼ 8.8, 1C, C(Ar)), 136.3e121.3 (om, 40C, CH(Ar)), 603 
79.0 (pt, 2JCP ¼ 3JCP ¼ 5.0, 1C, OCH), 78.2 (dd, 2JCP ¼ 5.0, 3JCP ¼ 2.5, 1C, OCH), 71.8 (dd, 604 
2JCPtrans ¼ 40.7, 2JCPcis ¼ 4.0, 1C, CH2(allyl)), 71.4 (dd, 2JCPtrans ¼ 40.8, 2JCPcis ¼ 4.2, 1C, 605 
CH2(allyl)), 69.3 (bs, 1C, CH(Cy)), 69.1 (bs, 1C, CH(Cy)), 65.7 (t, 2JCP ¼ 4.0, 2C, CH(Cy)), 51.9 (d, 606 
2JCP ¼ 21.3, 1C, CH2(Bn)), 51.3 (d, 2JCP ¼ 20.1, 1C, CH2(Bn)), 47.8 (d, 2JCP ¼ 7.5, 1C, CH2(Bn)), 607 
47,7 (d, 2JCP ¼ 8.8, 1C, CH2(Bn)), 30.5e29.7 (om, 4C, CH2(Cy)), 24.1 (s, 1C, CH2(Cy)), 24.0 (s, 1C, 608 
CH2(Cy)), 23.9 (s, 1C, CH2(Cy)), 23.8 (s, 1C, CH2(Cy)), 23.4 (s, 1C, CH3(allyl)), 18.9 (d, 3JCP ¼ 3.4, 609 
1C, CH3), 18.8 (d, 3JCP ¼ 2.6, 1C, CH3). HR-MS (ESI, m/z): calcd for C48H63N4O2P2Pd 895.3461, 610 
found 895.3465 [M]þ. 611 
 612 
3a-(S,S;Sal,Sal;S,S) 613 
 Yield: 190.0 mg (38%). Mp: 130e147 C. HR-MS (ESI, m/z): calcd for C48H63N4O2P2Pd 895.3461, 614 
found 895.3444 [M]þ. 31P {1H} (CDCl3, 121.4 MHz), 1H NMR (CDCl3, 500 MHz) and 13C NMR 615 
(CDCl3, 125.7 MHz) were described for 3a-(R,R;Ral,Ral;R,R) complex. HR-MS (ESI, m/z): calcd for 616 
C48H63N4O2P2Pd 895.3461, found 895.3444 [M] 617 
 618 
3b-(R,R;Ral,Ral;R,R) 619 
 Yield: 200 mg (39%). Mp: 170e173 C dec. 31P{1H} NMR (101.2 MHz, CDCl3, d (ppm), J (Hz)): 620 
121.5 (d, 2JPP ¼ 92.0), 118.7 (d, 2JPP ¼ 92.0). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 621 
7.66e6.77 (om, 40H, CH(Ar)), 4.54e4.31 (om, 4H, 2OCH2 þ 2CH2(Bn)), 4.26e4.12 (ms, 4H, CH2(Bn)), 622 
4.07 (dd, 2JHH ¼ 15.0 3JHP ¼ 10.0 1H, CH2(Bn)), 3.94 (bs, 1H, CH2(syn)), 3.84e3.68 (om, 3H, 623 
1CH2(Bn) þ 2OCH), 3.80 (bs, 1H, CH2(syn)), 3.35 (m, 2H, 2OCH2), 3.07 (m, 2H, CH(Cy)), 2.86 624 
(m,1H, CH(Cy)), 2.73 (m, 1H, CH(Cy)), 2.49 (d, 2JHH ¼ 15.0, 1H, CH2(anti)), 2.23 (d, 2JHH ¼ 15.0, 625 
1H, CH2(anti)), 2.05e0.98 (om, 16H, CH2(Cy)), 1.60 (s, 3H, CH3(allyl)), 1.30 (s, 3H, CH3), 1.28 (s, 626 
3H, CH3). 13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J (Hz)): 164.3 (q, 1JCB ¼ 48.8, 4C, CB(Ar)), 627 
138.9 (pt, JCP ¼ 8.1 1C, C(allyl)), 138.0 (d, 3JCP ¼ 3.8 1C, C(Ar)), 137.8 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 628 
137.7 (d, 3JCP ¼ 3.8, 1C, C(Ar)), 137.1 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 129.5e121.6 (40C, CH(Ar)), 111.2 629 
(s, 1C, O2CMe2), 77.5 (d, 3JCP ¼ 3.8, 1C, OCH), 77.3 (d, 3JCP ¼ 2.5, 1C, OCH), 70.7 (dd, 2JCPtrans 630 
¼ 43.8, 2JCPcis ¼ 3.8, 1C, CH2(allyl)), 69.2 (dd, 2JCPtrans ¼ 43.8, 2JCPcis ¼ 5.0, 1C, CH2(allyl)), 631 
67.4 (d, 2JCP ¼ 16.3, 1C, OCH2), 66.9 (d, 2JCP ¼ 16.3, 1C, OCH2), 66.7 (s, 1C, CH(Cy)), 66.5 (s, 1C, 632 
CH(Cy)), 65.9 (d, 2JCP ¼ 6.3, 1C, CH(Cy)), 65.3 (d, 2JCP ¼ 5.0, 1C, CH(Cy)), 49.4 (d, 2JCP ¼ 18.8, 633 
1C, CH2(Bn)), 48.7 (d, 2JCP ¼ 18.8, 1C, CH2(Bn)), 47.1 (d, 2JCP ¼ 11.3, 1C, CH2(Bn)), 46.8 (d, 634 
2JCP ¼ 11.3, 1C, CH2(Bn)), 29.7e29.4 (4C, CH2(Cy)), 26.6 (s, 1C, CH3), 26.6 (s, 1C, CH3), 24.1 (d, 635 
3JCP ¼ 3.8, 2C, CH2(Cy)), 23.9 (s, 1C, CH3(allyl)), 23.8 (d, 3JCP ¼ 1.3, 2C, CH2(Cy)). HR-MS (ESI, 636 
m/z): calcd for C51H67N4O4P2Pd 967.3672, found 967.3675 [M]þ. 637 
 638 
3d-(R,R;Ral,Ral;R,R) 639 
 Yield: 104 mg (21%). Mp: 159e166 C dec. 31P{1H} NMR (101.2 MHZ, CDCl3, d (ppm), J (Hz)): 640 
134.1 (d, 2JPP ¼ 87.1), 129.2 (d, 2JPP ¼ 87.1). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 641 
7.72e6.68 (om, 40H, CH(Ar)), 4.43 (pt, 2JHH ¼ 3JHP ¼ 16.0, 1H, CH2(Bn)), 4.31 (pt, 2JHH ¼ 3JHP ¼ 642 
15.0, 1H, CH2(Bn)), 4.14 (pt, 2JHH ¼ 3JHP ¼ 15.0, 1H, CH2(Bn)), 4.09e3.73 (om, 6H, 4CH2(Bn) þ 643 
2OCH), 4.04 (bs, 1H, CH2(syn)), 4.01 (bs, 1H, CH2(syn)), 3.64 (dd, 2JHH ¼ 16.5, 3JHP ¼ 7.5, 1H, 644 
CH2(Bn)), 3.07 (m, 2H, CH(Cy)), 2.87 (m, 1H, CH(Cy)), 2.79 (m, 1H, CH(Cy)), 2.56 (d, 2JHP ¼ 10.0, 645 
1H, CH2(anti)), 2.47 (d, 2JHP ¼ 15.0, 1H, CH2(anti)), 2.10e0.81 (om, 24H, 16CH2(Cy) þ 8CH2), 1.45 646 
(s, 3H, CH3(allyl)). 13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J (Hz)): 164.3 (q, 1JCB ¼ 48.8, 647 
4C,CB(Ar)), 140.2 (pt, JCP ¼ 8.1, 1C, C(allyl)), 138.5 (s, 1C, C(Ar)), 138.4 (s, 1C, C(Ar)), 138.3 (s, 648 
1C, C(Ar)), 138.2 (s, 1C, C(Ar)), 128.7e121.7 (40C, CH(Ar)), 80.1 (bs, 1C, OCH), 79.5 (bs, 1C, OCH), 649 
71.7 (dd, 2JCPtrans ¼ 25.0, 2JCPcis ¼ 2.5 1C, CH2(allyl)), 71.4 (dd, 2JCPtrans ¼ 23.8, 2JCPcis ¼ 2.5, 650 
1C, CH2(allyl)), 69.5 (bs, 1C, CH(Cy)), 69.1 (bs, 1C, CH(Cy)), 65.8 (pt, 2JCP ¼ 5.0, 2C, CH(Cy)), 52.4 651 
(d, JCP ¼ 22.5, 1C, CH2(Bn)), 51.6 (d, JCP ¼ 20.0, 1C, CH2(Bn)), 47.8 (d, 2JCP ¼ 6.3, 1C, CH2(Bn)), 652 
47.7 (d, 2JCP ¼ 8.8, 1C, CH2(Bn)), 32.6 (bs, 2C, CH2), 30.6 (s, 1C, CH2(Cy)), 30.2 (s, 1C, CH2(Cy)), 653 
30.0 (d, 3JCP ¼ 8.8, 1C, CH2(Cy)), 29.9 (d, 3JCP ¼ 7.5, 1C, CH2(Cy)), 24.2e23.9 (6C, 2CH2 þ 654 
4CH2(Cy)), 23.4 (s, 1C, CH3(allyl)). HR-MS (ESI, m/z): calcd for C50H65N4O2P2Pd 921.3618, found 655 
921.3618 [M]þ. 656 
 657 
3e-(R,R;Ral,Ral;R,R) 658 
 Yield: 91 mg (25%). Mp: 174e178 C dec. 31P{1H} NMR (101.2 MHZ, CDCl3, d (ppm), J (Hz)): 659 
131.5 (d, 2JPP ¼ 90.4), 130.1 (d, 2JPP ¼ 90.4). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 660 
7.88e6.87 (om, 20H, CH(Ar)), 4.34 (m,1H, OCH), 4.24 (m, 1H, OCH), 3.89 (bs, 1H, CH2(syn)), 3.80 661 
(bs, 1H, CH2(syn)), 2.86 (d, 2JHP ¼ 15.0, 1H, CH2(anti)), 2.77 (m, 2H, CH(Cy)), 2.68 (d, 2JHP ¼ 15.0, 662 
1H, CH2(anti)), 2.65 (d, 2JHP ¼ 14.4, 3H, CH3(NMe), 2.53 (d, 2JHP ¼ 14.6, 3H, CH3(NMe), 663 
2.55e2.43 (om, 2H, CH(Cy)), 2.51 (d, 2JHP ¼ 14.5, 3H, CH3(NMe)), 2.45 (d, 2JHP ¼ 14.8, 3H, 664 
CH3(NMe), 2.06 (m, 4H, CH2(Cy)), 1.87 (m, 4H, CH2(Cy)),1.72 (s, 3H, CH3(allyl)),1.37e1.08 (m, 8H, 665 
CH2(Cy)),1.27 (d, 3JHP ¼ 5.0, 3H, CH3), 1.25 (d, 3JHP ¼ 5.0, 3H, CH3). 13C{1H} NMR (125.7 MHz, 666 
CDCl3, d (ppm), J (Hz)): 164.2 (q, 1JCB ¼ 48.8, 4C, CB(Ar)), 139.2 (pt, JCP ¼ 8.1, 1C, C(allyl)), 667 
136.3 (s, 8C, CH(Ar)), 125.4 (s, 4C, CH(Ar)), 121.5 (s, 8C, CH(Ar)), 77.7 (m, 2C, OCH), 71.2 (dd, 668 
2JCPtrans ¼ 38.3, 2JCPcis ¼ 6.3, 1C, CH2(allyl)), 69.6 (dd, 2JCPtrans ¼ 38.8, 2JCPcis ¼ 6.3, 1C, 669 
CH2(allyl)), 68.5 (d, 2JCP ¼ 2.5, 1C, CH(Cy)), 68.4 (d, 2JCP ¼ 1.3, 1C, CH(Cy)), 64.4 (d, 2JCP ¼ 5.0, 670 
1C, CH(Cy)), 64.3 (d, 2JCP ¼ 5.0, 1C, CH(Cy)), 32.6 (d, 2JCP ¼ 20.0, 1C, CH3(NMe), 32.3 (d, 2JCP 671 
¼ 18.8, 1C, CH3(NMe), 29.5 (d, 2JCP ¼ 5.0, 1C, CH3(NMe), 29.1 (d, 2JCP ¼ 6.3, 1C, CH3(NMe), 672 
28.5 (d, 3JCP ¼ 2.5, 2C, CH2(Cy)), 28.1 (d, 3JCP ¼ 3.8, 1C, CH2(Cy)), 28.0 (d, 3JCP ¼ 5.0, 1C, 673 
CH2(Cy)), 24.3 (s, 1C, CH3(allyl)), 23.9 (s, 2C, CH2(Cy)), 23.8 (s, 1C, CH2(Cy)), 23.7 (s, 1C, 674 
CH2(Cy)), 19.7 (pt, 2JCP ¼ 3JCP ¼ 3.1, 2C, CH3). HR-MS (ESI, m/z): calcd for C24H47N4O2P2Pd 675 
591.2209, found 591.2208 [M]þ. 676 
 677 
4.3.4. Synthesis of [Pd(h3-2-CH3-C3H4)P2]PF6 (4f, 4g) and [Pd(h3-2-Me-C3H4)P2]BPh4 (5f) 678 
To a solution of the appropriate ligand (0.80 mmol) in toluene  (10 mL) at 0 C a solution of [Pd(h3-2-679 
CH3-C3H4)(m-Cl)]2 (79 mg, 0.20 mmol) in CH2Cl2 (5 mL) was added dropwise. Then a solution of 680 
NaPF6 (67 mg, 0.40 mmol) in THF (5 mL) was added. After 3 h of stirring at room temperature, the 681 
solution was washed with  deoxygenated water (2  4 mL). The organic phase was dried over anhydrous 682 
Na2SO4, filtered off and the solvent removed under reduced pressure. The white or yellow solid 683 
obtained was washed several times with diethyl ether or n-pentane and dried under reduced pressure. In 684 
case of 4f treatment of the CH2Cl2/THF solution with a solution  of NaBPh4 (204 mg, 0.60 mmol) in 20 685 
mL of MeOH resulted in formation of a white or pale-yellow powder. The solid formed on standing was 686 
filtered off and washed with deoxygenated water. 687 
 688 
4f-(R,R;Ral) 689 
Yield: 117 mg (49%).  Mp 171e177 C dec. 31P{1H} NMR (101.2 MHz, CDCl3, d (ppm), J (Hz)): 690 
124.0 (d, 2JPP ¼ 85.2), 122.2 (d, 2JPP ¼ 85.2). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 691 
7.60e6.83 (om, 30H, CH(Ar), 5.36 (m, 1H, OCH), 5.27 (m, 1H, OCH), 4.54 (pt, 2JHH ¼ 3JHP ¼ 16.0, 692 
1H, CH2(Bn)), 4.50 (bs, 1H, CH2(syn)), 4.41e3.97 (om, 5H, CH2(Bn)), 4.32 (bs, 1H, CH2(syn)), 693 
3.17e2.94 (om, 2H, CH(Cy)), 3.00 (d, 3JHP ¼ 13.6, 1H, CH2(anti)), 2.88 (d, 3JHP ¼ 13.6, 1H, 694 
CH2(anti)), 2.81e2.54 (om, 4H, 2CH2(Bn) þ 2CH(Cy)), 2.07 (om, 2H, CH2(Bn)), 1.87 (s, 3H, 695 
CH3(allyl)), 1.74 (om, 2H, CH2(Bn)), 1.60 (om, 2H, CH2(Bn)),1.51e0.80 (om, 10H, CH2(Cy)), 1.33 (d, 696 
3JHH ¼ 6.5, 3H, CH3), 1.22 (d, 3JHH ¼ 6.5, 3H, CH3). 13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), 697 
J (Hz)): 142.6 (s, 1C, C(Ar)), 142.4 (s, 1C, C(Ar)), 139.6 (d, 3JCP ¼ 8.0, 1C, C(Ar)), 139.3 (d, 3JCP ¼ 698 
9.0, 1C, C(Ar)), 138.8 (d, 3JCP ¼ 4.0, 1C, C(Ar)), 138.7e138.5 (2C, 1C(Ar) þ 1C(allyl)), 129.0e125.3 699 
(30C, CH(Ar)), 75.2 (d, 2JCP ¼ 2.0, 1C, OCH), 75.1 (bs, 1C, OCH), 71.4 (dd, 2JCPtrans ¼ 42.0, 700 
2JCPcis ¼ 4.0, 1C, CH2(allyl)), 70.8 (dd, 2JCPtrans ¼ 41.5, 2JCPcis ¼ 3.5, 1C, CH2(allyl)), 67.8 (bs, 701 
1C, 1CH(Cy), 67.6 (bs, 1C, 1CH(Cy), 67.1 (pt, 2JCP ¼ 5.0, 2C, CH(Cy)), 50.8 (d, 2JCP ¼ 20.0, 1C, 702 
CH2(Bn)), 50.2 (d, 2JCP ¼ 19.0, 1C, CH2(Bn)), 47.2 (d, 2JCP ¼ 10.0, 1C, CH2(Bn)), 46.6 (d, 2JCP ¼ 703 
10.0, 1C, CH2(Bn)), 30.6 (s, 1C CH2(Cy)), 30.6e30.4 (4C, CH2(Cy)), 26.1 (d, 3JCP ¼ 5.0, 1C, CH3), 704 
25.8 (d, 3JCP ¼ 6.0, 1C, CH3), 24.3e23.8 (4C, CH2(Cy)), 23.4 (s, 1C, CH3(allyl)). HR-MS (ESI, m/z): 705 
calcd for C60H73N4O2P2Pd 1049.4244, found 1049.4251 [M]þ. Anal. Calcd. for 706 
C60H73F6N4O2P3Pd: C 60.28, H 6.15, N 4.69%; found: C 58.60, H 6.29, N 5.14%. 707 
 708 
4g-(R,R;Sal) 709 
 Yield: 143 mg (57%). Mp: 179e184 C dec. 31P{1H} NMR (101.2 MHz, CDCl3, d (ppm), J (Hz)): 710 
126.3 (d, 2JPP ¼ 76.2), 119.6 (d, 2JPP ¼ 76.2). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 711 
7.65e6.75 (ms, 20H, CH(Ar)), 4.99 (dd, 2JHH ¼ 15.0, 3JHP ¼ 10.0, 1H, CH2(Bn)), 4.79 (pt, 2JHH ¼ 712 
3J HP ¼ 16.5, 1H, CH2(Bn)), 4.49 (m, 1H, OCH), 4.45e3.85 (om, 6H, 5CH2(Bn) þ 1OCH), 4.24 (bs, 713 
1H, CH2(syn)), 3.93 (bs, 1H, CH2(syn)) 3.76 (dd, 2JHH ¼ 16.5 3JHP ¼ 7.5, 1H, CH2(Bn)), 3.19 (m, 714 
2H, CH(Cy)), 2.94 (m, 2H, CH(Cy)), 2.64 (d, 3JHP ¼ 15.0, 1H, CH2(anti)), 2.43e0.65 (ms, 715 
30H,16CH2(Cy) þ 12CH2 þ 2CH(Cy)),1.90 (bs, 1H, CH2(anti)), 1.64 (s, 3H, CH3(allyl)), 0.99 (s, 3H, 716 
CH3), 0.90 (s, 6H, CH3), 0.84 (s, 3H, CH3), 0.80 (s, 3H, CH3), 0.47 (s, 3H, CH3). 13C {1H} NMR 717 
(125.7 MHz, CDCl3, d (ppm), J (Hz)): 138.9 (d, 3JCP ¼ 5.0, 1C, C(Ar)), 138.7 (d, 3JCP ¼ 8.8, 1C, 718 
C(Ar)), 137.7e137.6 (3C, 2C(Ar) þ 1C(allyl)), 129.1e126.4 (20C, CH(Ar)), 84.3 (d, 2JCP ¼ 15.0, 1C, 719 
OCH), 83.4 (d, 2JCP ¼ 15.0, 1C, OCH), 74.8 (d, 2JCPtrans ¼ 42.5, 1C, CH2(allyl)), 70.3 (d, 2JCPtrans 720 
¼ 41.3, 1C, CH2(allyl)), 68.8 (d, 2JCP ¼ 5.0, 1C, CH(Cy)), 67.8 (d, 2JCP ¼ 3.8, 1C, CH(Cy)), 65.8 (bs, 721 
1C, CH(Cy)), 65.0 (bs, 1C, CH(Cy)), 50.3 (d, 2JCP ¼ 3.8, 1C, CH2(Bn)), 49.7 (d, 2JCP ¼ 5.0, 1C, 722 
CH2(Bn)), 47.4 (d, 2JCP ¼ 13.8, 2C, CH2(Bn)), 44.6 (s, 1C, CH), 44.4 (s, 1C, CH), 38.0 (d, 3JCP ¼ 723 
5.0, 2C, CH2), 29.9 (bs, 1C, CH2(Cy)), 29.7 (bs, 1C, CH2(Cy)), 28.7 (s, 1C, CH2(Cy)), 28.4 (s, 1C, 724 
CH2(Cy)), 27.1 (bs, 2C, CH2), 26.7 (bs, 2C, CH2), 24.7 (d, 3JCP ¼ 6.3 2C, CH2(Cy)), 23.7 (d, 3JCP ¼ 725 
2.5 2C, CH2(Cy)), 22.8 (s, 1C, CH3(allyl)), 19.8 (s, 1C, CH3), 19.7 (s, 1C, CH3), 18.9 (s, 2C, 2CH3), 726 
14.3 (s, 1C, CH3), 13.4 (s, 1C, CH3). HRMS (ESI, m/z): calcd for C64H89N4O2P2Pd 1113.5496, 727 
found 1049.4251 [M]þHR-MS (ESI, m/z): 1113.5496 [M]þ. 728 
 729 
5f-(S,S;Ral) 730 
Yield: 118 mg (43%).  Mp: 170e175 C dec. 31P{1H} NMR (101.2 MHz, CDCl3, d (ppm), J (Hz)): 731 
120.7 (d, 2JPP ¼ 83.5), 115.9 (d, 2JPP ¼ 83.5). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 732 
7.86e6.58 (m, 50H, CH(Ar)), 5.38 (m, 1H, OCH), 5.15 (m, 1H, OCH), 4.70 (pt, 2JHH ¼ 3JHP ¼ 15.0, 733 
1H, CH2(Bn)), 4.42 (pt, 2JHH ¼ 3JHP ¼ 16.0, 1H, CH2(Bn)), 4.28e3.54 (om, 6H, CH2(Bn)), 4.17 (bs, 734 
1H, CH2(syn)), 3.81 (bs, 1H, CH2(syn)), 3.28 (m, 2H, 2CH(Cy)), 2.83 (m, 2H, 2CH(Cy)), 2.50 (d, 735 
3JHP ¼ 15.0, 1H, CH2(anti)), 2.08 (d, 3JHP ¼ 15.0, 1H, CH2(anti)), 2.03e0.79 (om, 16H, CH2(Cy)), 736 
1.64e1.60 (om, 6H, 1CH3(allyl) þ 1CH3), 1.38 (d, 3JHH ¼ 6.5, 3H, CH3). 13C{1H} NMR  737 
(125.7 MHz, CDCl3, d (ppm), J (Hz)): 164.3 (q, 1JCB ¼ 48.4, 4C, CB(Ar)), 142.4 (d, 3JCP ¼ 1.3, 1C, 738 
C(Ar)), 142.1 (d, 3JCP ¼ 2.5, 1C, C(Ar)), 139.0 (d, 3JCP ¼ 6.3, 1C, C(Ar)), 138.8 (d, 3JCP ¼ 5.0, 1C, 739 
C(Ar)), 138.1 (pt, JCP ¼ 8.1, 1C, C(allyl)), 137.8 (d, 3JCP ¼ 3.8, 1C, C(Ar)), 137.6 (d, 3JCP ¼ 6.3, 1C, 740 
C(Ar)), 136.3 (s, 8C, CH(BPh4 - )), 129.0e125.5 (30C, CH(Ar)), 125.3 (s, 8C, CH(BPh4 - )), 121.6 (s, 741 
4C, CH(BPh4 - )), 76.1 (dd, 2JCP ¼ 36.3, 4JCP ¼ 3.8, 1C, OCH), 75.6 (dd, 2JCP ¼ 20.6, 4JCP ¼ 14.4, 742 
1C, OCH), 70.6 (dd, 2JCPtrans ¼ 36.3, 2JCPcis ¼ 2.5, 1C, CH2(allyl)), 70.2 (dd, 2JCPtrans ¼ 33.8, 743 
2JCPcis ¼ 2.5, 1C, CH2(allyl)), 67.1 (d, 2JCP ¼ 5.0 1C, CH(Cy)), 67.0 (bs,1C, CH(Cy)), 66.3 (d, 2JCP 744 
¼ 3.8, 1C, CH(Cy)), 66.0 (bs, 1C, CH(Cy)), 49.9 (d, 2JCP ¼ 18.8, 1C, CH2(Bn)), 47.6 (d, 2JCP ¼ 16.3, 745 
1C, CH2(Bn)), 47.2 (d, 2JCP ¼ 15.0, 1C, CH2(Bn)), 46.9 (d, 2JCP ¼ 11.3, 1C, CH2(Bn)), 30.4 (d, 746 
3JCP ¼ 6.3, 1C, CH2(Cy)), 29.6 (d, 3JCP ¼ 5.0, 1C, CH2(Cy)), 29.3 (bs, 1C, CH2(Cy)), 28.8 (d, 3JCP 747 
¼ 2.5, 1C, CH2(Cy)), 25.2 (d, 3JCP ¼ 3.8, 1C, CH3), 24.7 (d, 3JCP ¼ 5.0, 1C, CH3), 24.3 (s, 1C, 748 
CH2(Cy)), 24.2 (s, 1C, CH2(Cy)), 23.8 (s, 1C, CH2(Cy)), 23.7 (s, 1C, CH2(Cy)), 23.3 (s, 1C, 749 
CH3(allyl)). HR-MS (ESI, m/z): calcd for C60H73N4O2P2Pd 1049.4244, found 1049.4246 [M]þ. 750 
 751 
4.3.5. Synthesis of [Pd(h3-Ph2-C3H3)(P-P)]PF6 (6b) and [Pd(h3-Ph2C3H3)(P-P)]BPh4 (7a) 752 
6b-(R,R;Ral,Ral;R,R) 753 
To a solution of the b-(R,R;Ral,Ral;R,R) (0.40 mmol) in toluene  (10 mL) at 0 C a solution of [Pd(h3-754 
Ph2C3H3)(m-Cl)]2 (134 mg, 0.20 mmol) in CH2Cl2 (30 mL) was added dropwise. Then a solution of 755 
NaPF6 (67 mg, 0.40 mmol) in THF (10 mL) was added. After 3 h of stirring at room temperature, the 756 
solution was washed with  deoxygenated water (2  4 mL). The organic phase was dried over anhydrous 757 
Na2SO4, filtered off and the solvent removed under reduced pressure. The white or yellow solid 758 
obtained was washed several times with diethyl ether or n-pentane and dried under reduced pressure. 759 
 Yield: 365 mg (73%). Mp: 195e205 C dec. 31P{1H} NMR (101.2 MHz, CDCl3, d (ppm), J (Hz)): 760 
120.2 (d, 2JPP ¼ 140.4), 117.3 (d, 2JPP ¼ 140.4). 1H NMR (500 MHz, CDCl3, d (ppm), J (Hz)): 761 
7.94e6.75 (om, 30H, CH(Ar)), 6.57 (t, 3JHH ¼ 12.9, 1H, CHcentral(allyl)), 5.27e5.02 (m, 1H, 762 
CH2(Bn)), 5.20 (om, 1H, CH(anti), 5.09 (om, 1H, CH(anti), 4.63 (t, 2JHH ¼ 3JHP ¼ 16.5, 1H, 763 
CH2(Bn)), 4.47 (dd, 2JHH ¼ 15.2, 3JHP ¼ 6.8, 1H, CH2(Bn)), 4.40 (dd, 2JHH ¼ 15.8 3JHP ¼ 6.6, 1H, 764 
CH2(Bn)), 4.18e3.77 (om, 5H, 2OCH2 þ 3CH2(Bn)), 3.61 (m, 1H, OCH), 3.51e3.36 (m, 2H, 1OCH þ 765 
1CH2(Bn)), 2.90 (m, 2H, CH(Cy)), 2.46 (m, 1H, CH(Cy)), 2.21e0.34 (ms, 19H, 1CH(Cy) þ 16CH2(Cy) 766 
þ 2OCH2), 1.06 (s, 3H, CH3), 1.02 (s, 3H, CH3). 13C{1H} NMR (125.7 MHz, CDCl3, d (ppm), J 767 
(Hz)): 139.3 (d, 3JCP ¼ 7.5, 1C, C(Ar)),138.8 (d, 3JCP ¼ 6.3, 1C, C(Ar)), 138.0 (dd, 3JCP1 ¼ 7.5, 768 
3JCP2 ¼ 5.0, 1C, C(Ar, allyl)), 137.4 (d, 3JCP ¼ 10.0, 2C, C(Ar)), 137.0 (dd, 3JCP1 ¼ 7.5, 3JCP2 ¼ 769 
5.0, 1C, C(Ar, allyl)), 134.5e125.3 (30C, CH(Ar)), 115.1 (pt, JCP ¼ 10.6, 1C, CHcentral(allyl)), 110.5 770 
(s, 1C, O2CMe2), 92.3 (dd, 2JCPtrans ¼ 32.5, 2JCPcis ¼ 10.0, 1C, CH(allyl)), 85.4 (dd, 2JCPtrans ¼ 771 
35.0, 2JCPcis ¼ 11.3, 1C, CH(allyl)), 77.2 (bs, 1C, OCH), 76.6 (bs, 1C, OCH), 68.6 (s, 1C, CH(Cy)), 772 
67.1 (s, 1C, CH(Cy)), 65.8 (bs, 1C, OCH2), 65.7 (bs, 1C, OCH2), 63.8 (d, 2JCP ¼ 5.0, 1C, CH(Cy)), 773 
63.4 (d, 2JCP ¼ 5.0, 1C, CH(Cy)), 50.7 (d, 2JCP ¼ 20.0, 1C, CH2(Bn)), 49.5 (d, 2JCP ¼ 18.8, 1C,  774 
CH2(Bn)), 46.2 (d, 2JCP ¼ 10.0, 1C, CH2(Bn)), 46.0 (d, 2JCP ¼ 8.8, 1C, CH2(Bn)), 30.7 (s, 1C, 775 
CH2(Cy)), 30.2 (s, 1C, CH2(Cy)), 27.6 (d, 3JCP ¼ 5.0, 1C, CH2(Cy)), 27.5 (d, 3JCP ¼ 5.0, 1C, 776 
CH2(Cy)), 26.3 (s, 1C, CH3), 26.1 (s, 1C, CH3), 24.1 (s, 1C, CH2(Cy)), 23.8 (s, 1C, CH2(Cy)), 23.7 (s, 777 
1C, CH2(Cy)), 23.5 (s, 1C, CH2(Cy)). HR-MS (ESI, m/z): calcd for C62H73N4O4P2Pd 1105.4142, 778 
found 1105.4138 [M]þ. Anal. Calcd. for C62H73F6N4O4P3Pd: C 59.50, H 5.88, N 4.48%; found: C 779 
56.98, H 5.92, N 4.52%. 780 
 781 
7a-(R,R;Sal,Sal;R,R) 782 
To a solution of a-(R,R;Sal,Sal;R,R) (0.40 mmol) in toluene (10 mL)  at 0 C a solution of [Pd(h3-783 
Ph2C3H3)(m-Cl)]2 (134 mg, 0.20 mmol) in CH2Cl2 (30 mL) was added dropwise. Then a solution of 784 
NaPF6 (67 mg, 0.40 mmol) in THF (10 mL) was added. After 1 h of stirring at room temperature, a 785 
solution of NaBPh4 (204 mg, 0.60 mmol) in 20 mL of MeOHwas added. The white solid formed on 786 
standingwas filtered off and washed with deoxygenated water. 787 
 Yield: 189 mg (35%). Mp: 175e178 C dec. 31P{1H} NMR (101.2 MHz, CDCl3, d (ppm), J (Hz)): 788 
135.5 (d, 2JPP ¼ 152.4), 130.2 (d, 2JPP ¼ 152.4). 1H NMR (400 MHz, CDCl3, d (ppm), J (Hz)): 789 
7.57e6.85 (om, 50H, CH(Ar)), 6.55 (t, 3JHH ¼ 12.9, 1H, CHcentral(allyl)), 4.92e4.67 (om, 1H, 790 
CH2(Bn), 4.74 (bs, 1H, CH(anti)), 4.49 (pt, 2JHH ¼ 3JHP ¼ 16.4, 1H, CH2(Bn)), 4.43e4.07 (om, 5H, 791 
3CH2(Bn) þ 2OCH), 4.30 (bs, 1H, CH(anti)), 3.88e3.81 (om, 1H, CH2(Bn)), 3.47 (dd, 2JHH ¼ 16.0, 792 
3JHP ¼ 8.0, 1H, CH2(Bn)), 3.26 (dd, 2JHH ¼ 16.0, 3JHP ¼ 26.0, 1H, CH2(Bn)), 2.71 (m, 1H, 793 
CH(Cy)), 2.64 (m, 1H, CH(Cy)), 2.50e0.67 (om, 18H, 16CH2(Cy) þ 2CH(Cy)), 0.92 (d, 3JHH ¼ 4.0, 794 
3H, CH3), 0.77 (d, 3JHH ¼ 5.6, 3H, CH3). 13C{1H} NMR (100.6 MHz, CDCl3, d (ppm), J (Hz)): 795 
164.2 (q, 1JCB ¼ 49.0, 4C, CB(Ar)),138.5 (d, 3JCP ¼ 7.0, 1C, C(Ar)), 137.3 (s, 1C, C(Ar)), 136.8 (s, 796 
1C, C(Ar)), 136.3 (s, 1C, C(Ar)), 135.7 (dd, JCP1 ¼9.0, JCP2 ¼ 5.0, 1C, C(Ar, allyl)),134.8 (dd, 3JCP1 797 
¼8.5, 3JCP2 ¼ 6.5, 1C, C(Ar, allyl)), 129.8e121.7 (50C, CH(Ar)), 112.9 (pt, JCP ¼ 11.0, 1C, CHcentral 798 
(allyl)), 93.7 (dd, 2JCPtrans ¼ 36.2, 2JCPcis ¼ 8.0, 1C, CH(allyl)), 82.6 (dd, 2JCPtrans ¼ 40.0, 2JCPcis 799 
¼ 10.0, 1C, CH(allyl)), 79.5 (dd, 2JCP ¼ 28.0, 3JCP ¼ 14.0, 2C, OCH), 69.8 (d, 2JCP ¼ 3.0, 1C, 800 
CH(Cy)), 69.7 (d, 2JCP ¼ 3.0, 1C, CH(Cy)), 63.3 (d, 2JCP ¼ 5.0, 1C, CH(Cy)), 62.3 (d, 2JCP ¼ 5.0, 801 
1C, CH(Cy)), 51.9 (d, 2JCP ¼ 21.0, 1C, CH2(Bn)), 51.1 (d, 2JCP ¼ 20.0, 1C, CH2(Bn)), 47.8 (d, 2JCP 802 
¼ 8.0, 1C, CH2(Bn)), 47.2 (d, 2JCP ¼ 10.0, 1C, CH2(Bn)), 31.1 (d, 3JCP ¼ 2.0, 1C, CH2(Cy)), 30.5 803 
(bs, 1C, CH2(Cy)), 29.7 (bs, 1C, CH2(Cy)), 28.6 (s, 1C, CH2(Cy)), 27.9 (d, 3JCP ¼ 6.0, 1C, CH2(Cy)), 804 
24.0 (s, 1C, CH2(Cy)), 23.8 (d, 3JCP ¼ 17.0, 1C, CH2(Cy)), 23.7(d, 3JCP ¼ 12.0, 2C, CH2(Cy)), 17.7 805 
(s, 1C, CH3), 17.6 (s, 1C, CH3). HR-MS (ESI, m/z): calcd for C59H69N4O2P2Pd C62H73N4O4P2Pd 806 
1033.3931, found 1033.3937 [M]þ. 807 
Elemental analysis results of palladium complexes are generally outside the range viewed as adequate 808 
for establishing analytical purity. The presence of solvent molecules not removed after several hours 809 
under vacuum and/or bad combustion of the solid samples are probably the reasons of these bad 810 
elemental analysis values. In the experimental part are only shown the microanalysis results that are 811 
acceptable. 812 
31P{1H} NMR of complexes 2a-c, 2e, 4f, 4g and 6b show one heptuplet at d ¼ -144.0 ppm and 1J ¼ 813 
715 Hz of the PF6    anion. 814 
 815 
4.4. General procedure for palladium-catalyzed Allylic substitution 816 
4.4.1. Allylic alkylation of rac-3-acetoxy-1,3-diphenyl-1-propene 817 
Reactions were carried out into an Schlenk tube under N2 at  25 C. 0.01 mmol of the palladium 818 
precursor was dissolved in 8 mL of CH2Cl2. Then, 1 mmol of the substrate rac-3-acetoxy-1,3- diphenyl-819 
1-propene and 1.5 mmol of Na(CH(COOMe)2) were added to the solution. The mixturewas stirred at 820 
room temperature for 24 h. At the end of the reaction, the mixture was diluted with diethyl ether, washed 821 
with ammonium chloride solution    (3  10 mL) and water (2  10 mL). The organic phase was dried 822 
over anhydrous Na2SO4 and filtered off. After partially removing the solvent under reduced pressure, 823 
the solution was eluted through a short silica column with ethyl acetate. The conversion was determined 824 
by 1H NMR and the enantiomeric excess by HPLC on a Chiralcel-OD-H chiral column, using 825 
hexane/isopropanol 95/5 as eluent and a flow of 0.5 mL/min. 826 
 827 
4.4.2. Allylic alkylation of rac-3-acetoxy-1-ciclohexene 828 
The procedurewas analogous to that described for rac-3-acetoxy- 1,3-diphenyl-1-propene using rac-3-829 
acetoxy-1-ciclohexene as substrate. Purificationwas performed by column chromatography (SiO2: ethyl 830 
acetate). The conversion and enantiomeric excess were determined by GC on a CHIRALDEX DM 831 
column. 832 
 833 
4.4.3. Allylic amination of rac-3-acetoxy-1,3-diphenyl-1-propene 834 
The procedure was analogous to that described for allylic alkylation of rac-3- acetoxy-1,3-diphenyl-1-835 
propene, using 3 mmol of benzylamine as nucleophile and 4 mL of CH2Cl2. Conversion was 836 
determined by 1H NMR and enantiomeric excesses by HPLC on a Chiralcel-OD-H chiral column, using 837 
hexane/isopropanol 99/1 as eluent and a flow of 0.3 mL/min. 838 
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Legends to figures 935 
 936 
Figure. 1 Diamidophosphite ligands P-P and P used in this work (new ligands in red). (For 937 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of 938 
this article.) 939 
 940 
Scheme 1. Synthesis of dichloropalladium complexes 1a and 1c. 941 
 942 
Scheme 2. Synthesis of allyl palladium complexes 2a-c, 2e, 4f, 4g and 3a, 3b, 3d, 3e, 5f. 943 
 944 
Figure. 2  NOE contacts (blue) and exchange signals (red). (For interpretation of the references to 945 
colour in this figure legend, the reader is referred to the web version of this article.) 946 
 947 
Figure. 3 a) Molecular view of the complex 1a-(S,S;Sal,Sal;S,S), (ellipsoids drawn at 50% probability 948 
level). Hydrogen atoms have been omitted for clarity. b) lateral view of the coordination plane showing 949 
 the symmetric disposition of the ligand bridge. Selected distances (Å) and angles ( ): P1-Pd1 950 
2.2254(10), P2-Pd1 2.2172(11), Cl1-Pd1 2.3729(11), Cl2-Pd1 2.3488(11), N1-P1 1.666(3), N2-P1 951 
1.650(3), N3-P2 1.641(3), N4-P2 1.661(3), O1-P1 1.617(3), O2-P2 1.606(3); P2-Pd1-P1 90.79(4), Cl2-952 
Pd1-Cl1 92.43 (4), P2-Pd1-Cl2 88.00(4), P1-Pd1- Cl1 89.26(4). 953 
 954 
Figure. 4 Molecular view of the cation corresponding to the complex 2e-(R,R;Ral,Ral;R,R) (ellipsoids 955 
drawn at 50% probability level). Hydrogen atoms and PF6    anion have been omitted for clarity. 956 
 Selected distances (Å) and angles ( ): Pd(2)-C(21A) 2.177(11), Pd(2)-C(22A) 2.196(11), Pd(2)-C(23A) 957 
2.173(11), Pd(2)-P(4) 2.262(3), Pd(2)-P(3) 2.276(2), P(3)-N(4A) 1.652(9), P(3)-N(3A) 1.672(8), P(4)-958 
N(1A) 1.654(9), P(4)-N(2A) 1.670(8), C(21A)-C(22A) 1.409(16), C(22A)-C(23A) 1.403(16); P(4)-959 
Pd(2)-P(3) 102.31(9), C(21A)-Pd(2)-C(23A) 67.4(4). 960 
 961 
Scheme 4. Asymmetric Allylic Alkylation of rac-3-acetoxy-1-cyclohexene (rac-IV) 962 
catalyzed by palladium complexes 963 
 964 
Scheme 5. Synthesis of allyl Palladium complexes 6b and 7a. 965 
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 Table 1 Selected 31Pa and 1Ha NMR data for complexes 2a-c, 2e, 3a, 3b, 3d, 3e, 4f, 4g, 5f. 1019 
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Table 2 Results of the asymmetric allylic substitution of rac-3-acetoxy-1,3-diphenyl-1-propene (rac-I). 1024 
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